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This work is

MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF A TANAPOX
VIRUS TNF-BINDING PROTEIN AND THE COMPLETE NUCLEOTIDE
SEQUENCE OF THE PstI-J GENOMIC FRAGMENT
Mini Paulose-Murphy, Ph.D.
Western Michigan University, 2000
Most of the poxv1rus encoded virulence factors have been identified as
proteins that are secreted from infected host cells. Some of these secretory proteins
impede host immune defenses. We have previously demonstrated that tanapox virus
(TPV) infected cells secrete a 38 k.Da glycopeptide that binds to human (h)
interferon-y, h-interleukin (IL)-2, and hIL-5. We now show an additional activity in
the supernatant from TPV infected cells that down-regulates the expression oftumor
necrosis factor-a (TNF-a) induced cell adhesion molecule gene expression. This
activity was not detected in mock infected cells. Enzyme linked immunosorbent
assays (ELISA) on primary human endothelial cells, show the induction ofE-selectin,
vascular cell adhesion molecule-I (VCAM-I), and intercellular adhesion molecule-I
(ICAM-I) following TNF-a or IL-I13 treatment, as expected. Supernatant from TPV
infected cells significantly decre�sed the TNF-a induced activation of the nuclear
transcription factor-KB (NF-KB) and transcriptional activation of the E-selectin,
VCAM-I7 and ICAM-I genes. Based on TNF-a affinity chromatography, this activity
appears to be associated with a 38 k.Da protein. This 38 k.Da protein was purified and
25 amino acid residues sequenced from the N-terminus. Multiple oligonucleotide

probes were designed from this protein sequence to identify the gene encoding the 38
kDa protein. The 5.1 kbp TPV PstI-J genomic fragment was isolated and both
strands completely sequenced. Analyses of the TPV PstI-J fragment revealed 7
potential open reading frames with significant homology to other poxviruses
including vaccinia virus and Yaba virus. Careful analyses of these open reading
frames did not reveal any homology to the N-terminal 25 amino acid sequence of the
38 kDa protein.
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INTRODUCTION
Poxviruses
Poxviruses are the largest and most complex of known animal viruses. The
family Poxviridae contains two subfamilies: the Chordopoxvirinae, which infect
vertebrates and the Entomopoxvirinae, which infect insects. There are eleven genera
of the Poxviridae family including the Avipoxvirus, Capripoxvirus, Leporipoxvirus,
Molluscipoxvirus, Orthopoxvirus, Parapoxvirus, Suipoxvirus, Yatapoxvirus, and
Entomopoxvirus A, B, and C. Viruses included in a genus are related both genetically
and immunologically and have a similar ultramicroscopic structure and host range
(reviewed in Moss, 1996). Many strains exist that are pathogenic to various host
· species. The most recognized poxvirus, variola virus, the causative agent of smallpox
in humans, is an extremely infectious agent that caused widespread disease. Today, it
is mostly of historical significance due to the campaign started in 1966 by the World
Health Organization for its worldwide eradication.
Poxviruses have contributed significantly m the advancement of both
biomedical and basic molecular biology. In 1796, Edward Jenner used cowpox virus
to vaccinate against smallpox. Later, vaccinia virus was used to replace cowpox virus
and eventually aided in the eradication of the scourge. In molecular biology, vaccinia
virus was the first mammalian virus to be visualized with light microscopy and
biochemically characterized. Today, vaccinia virus is used in recombinant techniques
(Mackett et al., 1982), where the viral genome provides a vector for the insertion of
1
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foreign genes in vaccine development.
Poxviruses are unique among DNA viruses in that their entire replication
cycle occurs in the cytoplasm of host cells. All species except tanapox produce pocks
on the chorioallontoic membrane in embryonated chicken eggs (Fenner, 1996).
Virion Structure
Poxviruses have a characteristic oval or "brick-shaped" structure (Figure 1).
Analyses of vaccinia virus reveals the dry weight of the virion to be composed of
90% protein, 5% lipid, and 3.2% DNA (Smadel and Hoagland, 1942, Zartouw, 1964).
Poxviruses are large, complex particles measuring 300-450 nm x 170-260 nm and can
be visualized by a light microscope using the oil immersion lens. Thin sections under
Lateral body
____ DNA
_____ Core
Outer envelope

Lateral body
Figure I. Diagram of the Poxviral Structure. Poxviruses are brick-shaped. A
biconcave core, flanked by two lateral bodies, contains the viral genome.
Two membranes are found on extracellular, enveloped virions.
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electron microscopy reveal an outer surface composed of lipid and proteins
surrounding a biconcave or dumbbell-shaped core (DeHarven and Yohn, 1966). The
core, studded with 20 run tubular structures (Moss, 1996), is enclosed by two lateral
bodies whose functions are unknown. The double-stranded, linear poxviral DNA is
found within the core unit. During replication, 2 forms .of viral particles are observed.
The intracellular mature virions (IMV) posses a single inner membrane and the
extracellular enveloped virions (EEV) (Payne, 1978) contain an additional
extracellular or outer lipoprotein envelope.
Viral Genome Structure and Organization
Poxviruses are double-stranded, linear DNA viruses with genomes ranging
from 130 kilobase pairs (kbp) inparapoxviruses (Menna et al., 1979, Robinson et al.,
1987) to approximately 300 kbp in avipoxviruses (Hyde et al., 1967). Complete
nucleotide sequences of vaccinia virus (Goebel et al., 1990) and variola virus
(Massung et al., 1993) confirms a conservation of sequences along the central regions
and variation in the termini (Mackett and Archard, 1979), where inverted terminal
repeats (ITRs) are found. ITRs are identical but oppositely oriented sequences. In
variola virus (Figure 2), the ITR sequence is small, approximately 725 base pairs
(hp), and contains three 69 hp direct terminal elements, and a 54 bp partial repeat
element (Massung et al., 1994). Since inverted terminal repeats may include coding
regions, some genes are found at both ends of the genome (Moss, 1996). Proximal to
the ITR region, terminal hairpin loops have been identified in vaccinia virus (Garon et
al., 1978), variola virus (Massung et al., 1994), cowpox virus (Pickup et al., 1983),

4
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Figure 2. Structure and Organization of the Vaccinia Virus Genome. Poxviral DNA
is linear and double-stranded. Tenninal loops link both strands at the
termini. Inverted terminal repeats are found proximal to the hairpin linked
ends. Conserved sequences are centrally located on the genome whereas
variable regions exist near the tennini.
(from Moss, 1996)
Shope fibroma virus (DeLange et al., 1984), swinepox (Massung and Moyer, 1991),
and others (Esposito and Knight, 1985).

The hairpin loops are largely but

incompletely base-paired and extrahelical bases exist on one of the two strands
(Baroudy et al., 1982). These genes are variable in poxviruses and may contain genes
that are nonessential for replication in tissue culture (Kotwal and Moss, 1988a, Perkus
et al., 1991).

The terminal regions may therefore also contain numerous genes

encoding many potentially novel proteins. Sequencing and computer analysis of the
left (52,283 bp) and right (49,649 bp) regions of the cowpox virus revealed 51 and 37
potential open reading frames (ORFs), respectively (Shchelkunov et al., 1998).
Adjacent to the hairpin loop is a region about 100 bp which is highly
conserved and essential to the virion (Moss, 1996). Internal to this region exist
tandem repeats of short AT-rich sequences which are thought to play important roles
in recombinational events.
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Poxviral genomes do not contain introns. The promoter regions are short and
are found directly upstream of the transcriptional and translational start sites
(reviewed in Traktman, 1991). The complete genomic sequence of several poxvirus
genomes have been sequenced including the Copenhagen (Goebel et al., 1990) and
Ankara (Antoine et al., 1998) strains of vaccinia virus,.the India (Shchelkunov et al.,
1993b), Bangladesh (Massung et al., 1994), and Western Reserve strains (Earl and
Moss, 1993) of the variola virus as well as the molluscum contagiosum virus
(Senkevich et al., 1996, Senkevich et al., 1997), the Shope (rabbit) fibroma virus
(Willer et al., 1999), the myxoma virus (Cameron et al., 1999), and the Melanoplus
sanguinipes entomopoxvirus (Afonso et al., 1999). There are approximately 200

genes in the genome.
Viral Infection Cycle
•

Poxviruses are taken up by the host cell through the process of active

ingestion or pinocytosis (Joklik, 1968). Viral particles are converted to viral cores in
the cytoplasm of the host cell almost immediately following entry to the cell (Joklik,
1964a, Joklik, 1964b, Sarov and Joklik, 1972) (Figure 3). This is the first uncoating
process. The viral cores contain the poxviral genome and a pool of proteins including
the RNA polymerase, capping/termination protein, poly A polymerase, and early
transcription factor (Moss, 1990, Moss, 1996). It is within the viral cores that some
early transcription occurs (Kates and McAuslan, 1967, Dahl and Kates, 1970a, Dahl
and Kates, 1970b, Polisky and Kates, 1972). These early mRNAs are released from
the core and translated on host polysomes (reviewed in Traktman, 1991), resulting in
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DNA
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Schematic Representation of the Poxviral Infection Cycle. The entire .
replication cycle of poxviruses occurs in the cytoplasm of host cells.
Poxviral particles are taken up by the cell through active ingestion. Viral
particles are converted to viral cores. A temporal cascade of gene
expression follows. Early genes are expressed before viral genome
replication and late genes are expressed only after viral DNA synthesis.
Poxviral DNA synthesis and assembly of the virus follows. Two forms of
the infectious particles can be seen, the intracellular mature virus (IMV)
and the extracellular enveloped virus (EEV).

an uncoating enzyme that removes the viral coat. In vaccinia virus, early mRNA can
be detected within 20 minutes and peak levels can be seen within 2-3 hours (Baldick
and Moss, 1993) after viral infection.

The transcription of these early genes is

regulated by Afr rich sequences, TAAAATG (Broyle and Moss, 1986), that are
located immediately upstream, of the RNA start sites (Cochran et al., 1985, Ink and
Pickup, 1989, Weir and Moss, 1987). The downstream sequence, TTTT-TAT is the
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early transcription termination signal (Amano, et al., 1995). Early proteins produced
are crucial for viral DNA replication including thymidine kinase (Dubbs and Kit,
1964, Hruby and Ball, 1982, Weir et al., 1982) thymidylate kinase (Smith, et al.,
1989), ribonucleotide reductasc (Slabaugh et al., 1988, Tengelsen et al., 1988) and
dUTPase (Broyle, 1993).
Viral cores are then broken down following a lag phase dependent on the
multiplicity of infection (m.o.i.). This is considered the secondary uncoating step
(Sarov and Joklik, 1972) resulting in naked viral DNA. A unique characteristic of
poxviruses is their ability to replicate viral DNA independent of the host cell nucleus.
This was shown in studies using enucleated BSC-1 cell monolayers infected with
vaccinia virus (Prescott et al., 1971, Prescott et al., 1972, Pennington and Follett,
1974). Levels of DNA synthesis were detected in the virus-infected cells despite the
absence of a nucleus.
Viral DNA is replicated in an organized area in the cytoplasm (Joklik and
Becker, 1964) termed viral factories (Fenner et al., 1989). As infection proceeds, an
enlargement of these areas can be seen. The viral genome is inclusive and encodes
almost all the proteins necessary for transcription and replication of the virus (Moss,
1992). The timing of DNA synthesis is dependent on the m.o.i., the cell type, and the
poxvirus itself Different members of the poxvirus family will vary in the period to
the onset of DNA replication ranging from 1-2 hours post infection (h.p.i.) for
vaccinia virus (Joklik and Becker, 1964) to 12-16 h.p.i. for the fowl poxvirus
(Prideaux and Boyle, 1987).
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DNA replication is postulated to begin with the introduction of a nick in
sequences proximal to the genomic terminus (Pogo, 1980, Pogo et al., 1981). The
resultant 3'0H primer terminus allows for the viral DNA polymerase to bind.
Folding back of this strand on itself enables DNA synthesis throughout the entire
genome and around the hairpin termini. It is unknown whether either terminus is
preferred. Concatemeric intermediates are formed during replication through the
hairpin (Moyer and Graves, 1981). The concatemer junction is made up of an
identical copy of the hairpin loop (Merchlinsky et al., 1988). Resolution of the
concatemer to unit length molecules occurs during late gene expression (Merchlinsky
and Moss, 1989). Studies using temperature sensitive mutants of vaccinia virus with
specific inhibitors show that concatemeric forms of DNA accumulate when late gene
expression is inhibited (DeLange, 1989, Merchlinsky and Moss, 1989). A main role
of DNA replication is in controlling the temporal cascade of gene expression
(reviewed in Traktman, 1991). It is DNA replication that induces the switch from
early gene synthesis to intermediate gene synthesis. This is a unique feature to
poxviruses and the African swine fever virus (Breese and DeBoer, 1966).
Intermediate genes are expressed following DNA replication but prior to late
gene expression (Moss and Salzman, 1968, Pennington, 1974, Vos and Stunnenberg,
1988). Few intermediate genes have been identified. Three known intermediate
genes encode transactivators of late genes (Keck et al., 1990).

The promoter

sequence of intermediate genes contains an initiator element, TAAA (Baldic\( et al.,
1992).

Intermediate mRNA levels in vaccinia virus peak at 100 minutes post

infection (Vos and Stunnenberg, 1988).
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Late gene expression begins on the derepression of intermediate genes. In
vaccinia virus, late stage mRNA can be detected at 140 minutes post-synchronous
infection.

Late genes are expressed only after genome replication since late

promoters are dependent on DNA replication for activity. Late genes synthesize
proteins involved in major virion structural components as well as virion enzymes
needed early during infection. The late genes are found throughout the genome but
cluster in the central region (Belle Isle et al., 1981). An initiation sequence of
TAAATG/A is found at the start of late open reading frames (ORFs) (Davison and
Moss, 1989b).
Assembly of the virus, as replication, occurs in the cytoplasm of infected
cells. Two distinct forms of infectious virus particles, intracellular mature virus
(IMV) and extracellular enveloped virus (EEV) (Payne, 1978), can be seen during
morphogenesis. The majority of the virus particles generated are IMV with EEV only
representing 1-10% of the total virus progeny in vaccinia virus (Payne, 1980). Both
forms are infectious but EEV appears to have a higher infectivity (Boulter and
Appleyard, 1973 ). IMV derive a double membrane from the trans-Golgi network to
form EEV. EEV migrate to the cell surface along actin-containing microfilaments
(Hiller et al., 1981). At the cell surface, EEV fuses its outer layer with the host cell
plasma membrane. Virions are subsequently released by budding (Payne, 1978).
Poxviral infection in tissue culture, halts host macromolecular synthesis.
Inhibition of host protein synthesis is well documented in the vaccinia virus (Moss
and Salzman, 1968). The time course of protein synthesis inhibition varies between
8-16 h.p.i. among poxviruses (Harper et al., 1979). However, the majority of host
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protein synthesis continues for as long as 72 h.p.i. in Yaba-infected cells (Vafai and
Rouhandeh, 1982).
Cytopathic Effect
The cytopathic effect that ensues poxvirus infection varies with virus strain
and cell type. In general, morphological cytopathogenesis involves the rounding of
infected cells followed by cytoplasmic granulation. In some cases, cell-cell fusion
has also been reported (reviewed in Traktman, 1991). Poxviral infection induces the
host cell to display a rapid alteration in cell shape and cytoskeletal reorganization
(Traktman, 1991). Microscopic observations also show that cytoplasmic inclusions
are correlated with poxvirus infection, as infection proceeds, an enlargement of these
areas can be seen.

At the molecular level, infection of tissue culture cells with

vaccinia virus or other orthopoxviruses results in changes in membrane permeability
(Carrasco and Esteban, 1982) and inhibition of host DNA, RNA, and protein
synthesis (Moss, 1996).
Some poxviruses including the Shope fibroma virus (Shope, 1932), Yaba
VIrus (Bearcroft and Jamieson, 1958), and molluscum contagiosum virus
(Postlethwaite, 1970) induce hyperplasia and even tumors in the skin of their hosts.
A nonessential gene encoding a homolog of epidermal growth factor (EGF) and
transforming growth factor-a. was discovered in vaccinia virus which was attributed
to the development of the hyperplastic response (Blomquist et al., 1984, Twardzik et
al., 1985, Buller et al., 1988b). In vivo experiments revealed that infection with wild

type virus caused rapid proliferation of ectodermal and endodermal cells of chicken
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embryo chorioallantoic membrane, whereas this was not seen in mutant virus lacking
the VGF gene (Buller et al., 1988a).
Poxvirus-Host Interactions
Viruses, in the most general sense, are obligate intracellular parasites. They
rely on their hosts for sources of energy and protein synthesis and are capable of
manipulating host cellular machinery to their needs. The host however possesses an
arsenal of defense molecules, in the form of the immune system which is efficient in
destroying inhibiting, and disabling the virus. The survival of the virus in vivo
therefore depends on its capacity to evolve modes of evasion, suppression, or
inactivation of the host immune system. The virus and host consequently engage in a
form of combat, once cleverly referred to as a form of "Star Wars" (Barinaga, 1992).
Survival and success of both the host and virus are at stake.
Viruses use a vast array of strategies to evade the immune response. RNA
viruses such as rhinovirus (Hayder and Mullbacher, 1996) and influenza virus (Wiley
et al., 1981) utilize antigenic variation as a means to escape host immune

components. This property allows the viruses to exist in multiple antigenically
distinct strains. Rhinoviruses and influenza viruses therefore depend on non-immune
hosts and rapid transmission from host to host for their survival.

The human

immunodeficiency virus (HIV) also utilizes a similar strategy of constant antigen
evolution to evade the immune system (Coffin, 1995). HIV however, can at any one
time exist in several dozen different . antigenic forms within a single infected
individual. Other viruses such as the poxviruses (Palumbo et al., 1994, Smith, 1993,
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Pickup, 1994, McFadden et al., 1995), adenoviruses (Wold and Gooding, 1991,
Hayder and Mullbacher, 1996), and herpesviruses (Hsu et al., 1990, Bhat and
Thimmappaya, 1983, Poynter-Davis and Farrell, 1996), which are antigenically
stable, use virally encoded protein homologs of host immune factors to evade the
immune response. These viral homologs are most likely genes acquired from their
hosts.
In the past 10 years, there has been a great advancement in the understanding
of these virally encoded proteins for defense.

To date a large set of viral protein

factors that contribute to virulence have been identified.

Modulators of the host

immune response include inhibitors of complement control proteins, apoptosis,
inflammation, and cytokine-receptor mimicking molecules. These immunomodulators
are virally encoded proteins possessing sequence similarity with host immune factors.
Members of the poxvirus family were the first DNA viruses shown to encode secreted
versions of cellular cytokine receptors (Smith et al., 1991).
Virokines (Kotwal and Moss, 1988b) and viroceptors (Upton et al., 1991) are
two terms coined to classify groups of viral defense molecules. Virokines are a group
of virally encoded proteins secreted from infected cells which function by mimicking
extra-cellular signaling molecules such as cytokines or other secreted regulators
(McFadden, 1995).

Virokines act to antagonize the effects of host signaling

molecules involved in the anti-viral response. Viroceptors are similar to virokines but
mimic cellular receptors and act by diverting cytokines from binding their normal
receptors. Both virally encoded proteins function to basically interrupt the "immune
circuitry" (McFadden, 1995) and provide the virus a means to propagate.
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Immunomodulating viral polypeptides may have potential therapeutic actions,
especially in autoimmune diseases, since they are capable of inactivating or inhibiting
cytokine activities. This review will encompass a wide array of virulence factors but
will focus primarily on poxvirus encoded virulence factors.
Homologs of the Complement System
The complement system is a highly regulated series of 20 functionally linked
proteins (Figure 4). The system functions principally in (a) cytolysis of foreign
organisms, (b) opsonization which enhances phagocytosis, and (c) activation of
inflammation by serving to promote chemotaxis of inflammatory cells and stimulate
the release of chemical inflammatory mediators from leukocytes (for review see
Muller-Eberhard, 1988, Reid and Day, 1989).
Two activation pathways exist for the complement system (Figure 4). The first, the
classical pathway, is activated by antibody-antigen complexes and the second, the
alternative pathway, is activated directly by microbial surfaces in the absence of
antibody. Although differing in their modes of activation, both pathways share many
late stages and effector functions. Their functions converge and lead to the formation
of the membrane attack complex (MAC) which induces the osmotic lysis of foreign
or virally infected cells (Muller-Eberhard, 1986). Complement-mediated lysis is an
important component of the host defense against microbial infection including
viruses.
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Viruses have evolved measures to counteract the activities of the complement
system (Figure 4). Surface glycoprotein C (gC) of the herpes simplex virus-I (HSV1) and -2 (HSV-2) functions as a C3b receptor. C3b is normally induced on cells
following HSV infection.

C3b is critical in both the classical and alternative

pathways of the complement system. Binding of . the C3b component of the
complement pathway to HSV-gC prevents complement lysis and virus neutralization
(Friedman et al., 1984, Fries et al., 1986, McNeamey et al., 1987, Harris et al., 1990).
The HSV-gC thereby very effectively inhibits both alternative and classical pathways
(Harris et al., 1990).
The gamma herpes virus saimiri (HVS) encodes two proteins, HVS 04 and
HVS 15 that interfere with complement activity. HVS 04 inhibits the classical
pathway (Fodor et al., 1995) by inhibiting C3-convertase activity. Fodor et al. (1995)
demonstrated that cells transfected with HVS 04 were resistant to complement
mediated cytolysis. This was attributed to the functional homology of HVS 04 to
decay accelerating factor (DAF), a protein which functions to inhibit the assembly of
C3 convertase. HVS 15 acts to prevent complement-mediated cytolysis by displaying
a strong homology to a complement component, CD59. CD59 inhibits assembly of
MAC by blocking C9 (Rother et al., 1994). By blocking the MAC, HVS potentially
enhances virus survival by inhibiting the destruction of virally infected cells.
The vaccinia virus complement-control protein (VCP) binds the C4b fragment
of complement component C4 (K.otwal and Moss, 1988b). VCP is a major 35 kDa
secretory protein that is structurally similar to the C4-binding protein. VCP was
shown to inhibit hemolysis of sensitized sheep erythrocytes in human serum by
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interfering with complement-mediated attack (Kotwal et al., 1990). VCP inhibits
complement fixation mediated by the classical pathway but not the antibody
independent alternative pathway (Kotwal et al., 1990). Animal studies show that there
is decreased virulence in mutant viruses lacking the gene encoding VCP (Kotwal et
al., 1990). By inhibiting the complement system, the virus can circumvent one of the

most important host responses for virus neutralization and cytolysis of virus-infected
cells.
Homologs of Cellular Cytokines and Their Receptors
Cytokines are protein molecules involved in the effector phases of both
natural and specific immunity. Cytokines are crucial for communication between
cells of the immune and inflammatory systems. In general, cytokines are synthesized
in response to inflammatory or antigenic stimuli and act locally in an autocrine or
paracrine fashion, by binding to high affinity receptors found on target cells.
Multiple and diverse cell types produce cytokines which themselves are
pleotropic and can act on various cells. The actions of cytokines can be redundant
and often influence the synthesis of other cytokines as well as their own actions.
Cytokines serve many functions that are critical in the host immune response against
pathogens and also regulate the magnitude and nature of the immune response.
Cytokines are an integral component of the host response to viruses. For example,
TNF-a. is crucial in antiviral activity by mediating the lysis of infected cells whereas
interferons act to protect uninfected cells from virus infection. Several viruses have
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acquired homologs of cytokines or cytokine receptor genes that they use to
manipulate the host cytokine network (Table I).
Inhibition of Tumor Necrosis Factor (TNF) and TNF Receptor Homologs
Activated mononuclear phagocytes and T,.cells synthesize TNF as a
nonglycosylated transmembrane protein of approximately 25 kDa.

A 17 kDa

fragment at the carboxy terminus, is proteolytically cleaved off the plasma membrane
to produce the secreted form, which circulates as a stable homotrimer of 51 kDa.
TNF exists in two homologous forms, TNF-a and TNF-J3.
Binding of the soluble TNF trimer to its cellular receptor initiates the activity
of this cytokine. TNF receptors are present on almost all cells. There are two distinct
tNF receptors of 55 kDa (p55) and 75 kDa (p75). They are expressed independently
on the membranes of cells and share 28% homology. Both TNF receptors bind TNF
a and TNF-J3. The receptors share no homology however in their intracellular
domains implying that they utilize different signaling pathways (Dembic et al., 1990).
They are members of the NGFffNF receptor superfamily which includes CD27,
CD30, CD40, and Fas antigen (Itoh et al., 1991, Camerini et al., 1991). These
receptors are defined by multiple cysteine-rich domains in the extra-cellular region,
each containing about 40 amino acids (Smith et al., 1994).
TNF is the principal mediator of the host response to infectious organisms,
including bacteria. It affects nearly every tissue and organ system (reviewed in
Dinarello, 1992). The biological actions of TNF include: (a) the upregulation of cell
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Table 1
Virus Encoded Host lmmunoregulatory Proteins
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adhesion molecules on vascular endothelial cells which are essential for the binding
of leukocytes at sites of inflammation and infection,

(b) the activation of

inflammatory leukocytes including morphonuclear leukocytes, (c) the stimulation of
mononuclear phagocytes and other cell types to produce cytokines, including IL-I
and TNF itself, and (d) the cytolysis of cells infected with certain viruses (reviewed in
Beutler and VanHuffel, 1994, Beutler and Cerami, 1989).
With the pleotropic nature of TNF, it is not surprising that viruses have
evolved mechanisms to suppress its activity. Adenoviruses are non-enveloped, DNA
viruses. The double-stranded DNA is transcribed in two phases, early and late, in the
nucleus of infected host cells. Among the 20-25 adenovirus early genes, there are at
least 4 gene products with anti-TNF activity. The E3-14.7k, E3-10.4k, and E3-14.5k
proteins are transcribed from the E3 region of the viral genome while the EIB-19k is
transcribed from the El region (reviewed in Wold and Gooding, 1991). These
proteins act to prevent TNF-induced cytolysis employing distinct mechanisms. E310.4k and E3-14.5k are transmembrane proteins present in the plasma membrane
(Hoffman et al., 1992) that function together as a heterodimer (Tollefson et al., 1991).
Hoffman et al. (1992) showed that in addition to inhibiting TNF-induced cytolysis,
that the E3-10.4k and E3-14.5k heterodimer further function to down-regulate the
epidermal growth factor receptor (EGFR). The E3-14.7k product is a 128 amino acid
protein found in the nucleus and cytoplasm of infected cells (Persson et al., 1979)
whereas the EIB-19k protein (Gooding et al., 1991) is found in the nuclear envelope
of infected cells. Unlike E3-10.4k and E3-14.5k, both E3-14.7k and EIB-19k act
independently to inhibit TNF activity. By conferring TNF resistance and EGF down-
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regulation to the virus, these four adenovirus proteins allow the adenovirus to escape
one component of the host immune response.
Several poxviruses have also acquired anti-TNF activity in the form of
homologs of the TNF receptor. These homologs are capable of binding TNF and
nullifying its activity.

The Shope fibroma virus- (SFV) is a member of the

leporipoxviruses. It is a tumorigenic virus which induces invasive malignancies in

immunocompromised rabbits and benign fibromas in adults rabbits (reviewed in
McFadden, 1988). SPV encodes a soluble receptor of the type I TNF receptor,
termed T2 (Smith et al., 1991). The T2 gene was isolated from the ITR regions of the
SFV genome and found to be an early gene (Upton et al., 1987). Recombinant T2
protein, expressed in COS cells, was secreted as a soluble glycoprotein with an
apparent molecular weight of 58 kDa (Smith et al., 1991). The cytoplasmic domain
of the T2 protein contains 129 amino acid residues with no sequence homology to any
known proteins. In TNF binding assays, T2 was shown to bind specifically to mouse
and human TNF-a. and TNF-f3, inhibit the binding of TNF-a. and TNF-f3 to their
native cellular receptors, and inhibit TNF-mediated cytolysis of murine L929
fibroblasts (Smith et al., 1991).

Statistical analysis comparing the T2 sequence with

those of all cellular TNF receptor family members established T2 as an acquired p75,
not p55, TNF receptor (Smith et al., 1990, Smith et al., 1991). T2 was the first
soluble cytokine receptor, specifically p75 TNF receptor, to be identified in a virus.
The myxoma virus, a pathogenic virus of European rabbits, which induces an
often fatal systemic infection (reviewed in McFadden et al., 1997), was subsequently
found to possess a TNF-binding protein. Upton et al. (1991) identified two copies of
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an M-T2 gene, one on each of the terminal regions of the myxoma genome. The M
T2 protein was shown to have significant homology to the ligand binding domain of
the TNF receptor gene family (Upton et al., 1991). When both copies of the M-T2
gene are inactivated, a dramatic disease attenuation is seen in infected rabbits. The
majority of the rabbits infected with the M-T2-knockout virus were able to mount an
effective immune response and recover from the otherwise fatal infection (Upton et
al., 1991). M-T2 is secreted from virally infected cells as both a monomer of 55-95
kDa and as a 90 kDa disulfide-linked dimer, both of which bind TNF-a with similar
affinities (Schreiber et al., 1996). The dimer however is a far more potent inhibitor of
TNF-a. The C-terminal contains a 132 amino acid sequence that is distinct and
unique to myxoma, although it is relatively conserved in some of the other poxviral
TNF homologs. The M-T2 protein inactivates TNF in a species specific manner
(Schreiber and McFadden, 1994). The cytolytic activities of rabbit TNF-a but not
mouse or human TNF-a are inhibited by M-T2. Scatchard analysis of the binding
specificities ofM-T2 (Schreiber et al., 1996) revealed that M-T2 binds to rabbit TNF
a with an affinity which is comparable to that of cellular receptors. These studies all
demonstrate that M-T2 is a powerful virulence factor of myxoma virus contributing to
viral pathogenesis.

It also further indicates the importance of TNF-a in viral

infections.
The cowpox virus, a member of the orthopoxviruses, was found to encode two
soluble homologs of the cellular TNF receptor termed CrmB and CrmC (Smith et al.,
1996). The crmB gene was identified in the ITR of the Brighton Red strain of the
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cowpox virus (Hu et al., 1994).

The crmB gene is transcribed from an early

promoter. Its primary product is a 355 amino acid protein containing a signal peptide
sequence and three potential N-link:ed glycosylation sites. The mature gene product
is secreted with an approximate molecular mass of 48 kDa. The CrmB protein can
bind TNF-cx and TNF-f3 (Hu et al. 1994). Analysis of the N-terminal sequence
further revealed close sequence homology with the human TNF receptor Type II.
The 161 amino acid C-terminal revealed no similarity to any human TNF receptor.
The CrmB protein shows 48% identity to leporipoxviruses and 85% identity to the
G4R/G2R ORF of variola virus. The crmC gene is a single copy gene and unlike
crmB, is expressed late during viral infection. The 186 amino acid secreted protein,
CrmC, is cysteine-rich, has two potential glycosylation sites, and an N-terminal,
which constitutes a signal peptide. A 25 kDa recombinant form of CrmC has been
shown to bind TNF specifically and completely inhibit TNF-mediated cytolysis. The
crmC gene has the strongest homology to the TNF type two receptor gene. Unlike
the CrmB protein, the CrmC protein does not bind TNF-f3 and lacks the conserved C
terminal domain of CrmB proteins.
Vaccinia virus is the prototype of poxviruses. It has a 190 kbp genome, which
has the capacity to encode over 200 proteins (Essani and Dales, 1979). The vaccinia
virus equivalent of the TNF receptor homolog shows a disruption in the ORF
(Howard et al., 1991). The introduction of downstream reading frame shifts however .
allows the 122 residue ORF, originally designated C22L (repeated as B28R in the
right ITR), to be assembled into almost a full complement of four cysteine-rich
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pseudorepeats.

Connection of three additional ORFs downstream from C22L

completes a coding region strongly homologous to the C-terminal element of T2.
The poxviral TNF receptor homologs are all located in the ITRs, near the
genomic termini. All TNF receptor homolog ORFs, except in vaccinia virus, are
encoded by a continuous nucleotide sequence. All the ORFs however have
remarkable sequence conservation in both the N-terminal, which is cysteine-rich, and
the C-terminal regions. Variola virus and cowpox virus, both orthopoxviruses, share
85% identity and SFV and myxoma virus, both leporlpoxviruses, are similarly
conserved (reviewed in Hu et al., 1994). The N-terminal sequence is conserved
although the C-terminal domain varies slightly between the viruses. M-T2 and SPV
T2 are transcriptionally early genes. The main function of these poxviral homologs is
viral inhibition of host-produced TNF.

The viral TNF receptor homologs have

structural and functional similarity to cellular TNF receptors that are probably their
evolutionary origin.
Inhibition of Interferon (IFN) and IFN Receptor (IFNR) Homologs
Gamma interferon (IFN-y), also called type II interferon, is produced by both
+
+
IL-2 secreting CD4 helper T-cells and almost all CD8 T-cells. IFN-y is crucially

involved in inducing an anti-viral state (Isaacs and Lindenmann, 1957). This is
primarily a paracrine function, in that virally infected cells secrete IFN-y to protect
neighboring cells not yet infected and thereby preventing viral proliferation. IFN-y is
also a potent activator of natural killer cells and the lytic potential of these cells which
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is crucial in destroying virally infected cells (Isaacs and Lindenmann, 1957). IFN-y
acts to increase the expression of class I MHC molecules, which are recognized by
cytolytic T-lymphocytes (CTL). In addition, IFN-y is also a potent stimulator of
mononuclear phagocytes and directly promotes differentiation of T- and B
lymphocytes (reviewed in McNair and Kerr, 1992). · IFN-y is also involved in the
+

activation of vascular endothelial cells, promoting CD4 T-cell adhesion. It can be
seen that IFN-y therefore is critical in the elimination of viral infection and in the
inflammatory response.
IFN-y itself does not directly prevent viral infection, but inlnbits viral spread
by induction of anti-viral pathways within the immune system (reviewed in McNair
and Kerr, 1992). PKR, a double-stranded RNA-dependent protein kinase, and 2-5A
synthetase are two enzymes induced by all IFNs (Farrell et al., 1977, Kerr_ and
Brown, 1978).

Activated PKR phosphorylates the a-subunit of the eukaryotic

translation initiating factor, eIF, an important component of cellular protein synthesis.
Phosphorylated eIF remains in a complex with eIF2�, preventing its recycling, and
thereby shutting down protein synthesis.

The vaccinia virus E3L and K3L

intracellular proteins (Chang et al., 1992, Davies et al., 1992) block RNA activation
and phosphorylation of eIF2-a, respectively. HIV and SIV have been shown to
down-regulate PKR, poliovirus has been shown to degrade PKR and EBY, reovirus
and influenza virus have been shown to inhibit activation of PKR (reviewed in
Mathews, 1993).
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Poxviruses are, to date, the only viruses shown to encode IFN-binding
proteins. The myxoma virus encodes an IFN-yR homolog, designated MT7, which is
found within the ITR regions of the viral genome (Upton et al., 1992).

The MT7

gene product is a 37 kDa soluble protein with sequence homology to both murine and
human IFN-yRs (Upton et al., 1992). The protein is expressed during early and late
times of infection. Mossman et al. (1995c) determined the prevalence of the MT7
protein throughout viral infection to be attributed to the stability of the viral mRNA
and not due to the constitutive expression of the viral rn.RNA. The MT7 protein is
secreted by 4 hours post-infection and is species-specific (Mossman et al., 1995c).
The MT7 protein only binds and inhibits the activity of rabbit IFN-yR not human or
mouse.
SFV also encodes an IFN-yR homolog, denoted ST2 (Upton et al., 1991) that
has been mapped to the SFV-ITRs (Upton et al., 1987, Upton et al., 1992). The ST2
gene product is a soluble protein composed of 265 amino acids and has 68%
homology to the MT7 gene. The ST7 protein is not expressed at levels as high as
MT2 although it is present at both early and late times of infection.
The Bl8R gene product of the Western Reserve (WR) strain of the vaccinia
virus binds type I IFN and blocks IFN-y transmembrane signaling (Goebel et al.,
1990). The Bl8R protein binds human IFN-y with a high affinity and cells infected
with the WR strain of the vaccinia virus, with an inactivated Bl 8R gene, failed to
bind radioiodinated IFN-y (Colamonici et al., 1995). Bl8R exists as a soluble form
(Alcami and Smith, 1995) and as a bound form (Ueda et al., 1990). In competition
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experiments, Colamonici et al. (1995) showed that 100µ1 of medium containing the
B18R gene product blocked binding ofIFN-y to the human receptor. The B18R gene
product interestingly was shown to neutralize the activity of human as well as rat
(Alcami and Smith, 1995) and chicken (Puehler et al., 1998) IFN-y. Since the origins
of vaccinia virus are still unclear, such findings bring us closer to determining its
ongms.
With the increasing knowledge of poxviral sequences, other IFNR homologs
are now being determined including the B8R of variola virus, Bangladesh-1975
strain, B9R of the variola virus, India-167 strain (Massung et al., 1993, Shchelkunov
et al., 1993), and the C6L protein of the swinepox virus (Massung et al., 1993).
Ectromelia virus of mice and the cowpox virus have also been identified to encode
IFN-yR homologs (Mossman et al., 1995b). Comparison of the poxviral IFN-yR
homologs reveal a conservation of 8 cysteine residues in the MT2, ST2, and C6L
proteins and 6 in the B8R and B9R proteins (Mossman et al., 1995b). All poxviral
IFN-yR homologs are secreted from infected cells and lack the transmembrane
domains (Mossman et al., 1995b). They all share significant homology to the human
IFN-yR but the extent of homology with the entire sequence is low with only 20-25%
identity (Mossman et al., 1995b).
Viral Protein Inhibitors of Apoptosis
Apoptosis or programmed cell death is an important component of the host
immune response against viral infection. Virally infected cells can undergo "suicide"

to limit viral multiplication. Viruses in tum have evolved mechanisms to inhibit
apoptosis. The Epstein-Barr virus (EBV) BhRF-1 protein shows homology to Bel-I,
a cellular protein inhibitor of apoptosis (Henderson et al., 1993, Tarodi et al., 1994).
BhRF-1 was shown to successfully protect human B-cells from undergoing apoptosis
(Henderson et al., 1993). The African swine fever virus LMW5-fil gene also shows
homology to Bcl-2 and BhRF-1 (Neilan et al., 1993). The adenovirus ElB-19k
protein has sequence similarity to Bcl-2 (Rao et al., 1992, Tarodi et al., 1993) and
inhibits apoptosis (White et al., 1991, Rao et al., 1992) by blocking p53, a well
known tumor suppressor protein which induces apoptosis (reviewed in Levine, 1993).
Several poxviruses have also been shown to encode anti-apoptotic genes including
the CHOhr of the cowpox virus (Ink et al., 1995), the SPI-1 from rabbitpox virus (Ali
et al., 1994), the SPI-2/crmA of the cowpox virus (Gagliardini et al., 1994, Ray et al.,

1992), and the myxoma virus, MT2 and M l IL (Macen et al., 1996, Upton et al.,
1987).
As more information on viral genes is generated through the growing DNA
sequence databases, new knowledge will be gained on the multi-functionality of
many of the known viral protein homologs of the host immune system. As with the
MT2 and the crmA genes, which were thought once to encode a TNFR homolog
(Upton et al., 1987) and interleukin-Ip converting enzyme (ICE) (Ray et al., 1992)
respectively, and now also believed to participate in anti-apoptotic roles (Tewari and
Dixit, 1995, Schreiber et al., 1997).
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Tanapox Virus
Tanapox virus (TPV), Yaba virus, and Yaba-like disease virus (YLDV) are
members of the Yatapoxvirus genus based on their size, shape, and ultrastructure.
Yatapoxviruses infect all primates but cause disease primarily in non-human primates.
Yatapoxviruses are antigenically related to one another but not to monkeypox or

vaccinia viruses (Niven et al., 1961, Downie et al., 1971). Due to similarities in
serological tests between TPV and YLDV, YLDV has been referred to in the
literature as being identical to TPV (Downie and Espana, 1972). However, restriction
maps (Knight et al., 1989) reveal that TPV and YLDV are clearly distinct viruses.
History
_ The first occurrence of TPV disease was in Ngua, an island swamp forest in
Kenya, Africa, in 1957 when a small group of school children developed disease
associated later with TPV. The virus was not isolated however until 1962 when a
larger outbreak occurred in a population living along the Tana River Valley in Kenya,
Africa (Downie et al., 1964). Outbreaks are now known to be endemic in the areas
of Kenya and Zaire (Axford and Downie, 1979). In Kenya, the epidemics seen in
1957 and 1962 were associated with periods of extensive flooding (Downie, 1971).
In Zaire cases are seen throughout the year but mostly between November and March
(Jezek et al., 1985). Most of these cases occurred in people living along the Zaire
nver.
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Virion Structure

TPV is similar to other poxviruses in that virions are enveloped with a brick
shaped or oval morphology (Figure 5) are large in size ranging from 280 x 200nm
and can be visualized by the best light microscope _(Downie et al., 1971). Thin
sections under electron microscopy reveal an outer surface composed of lipid and
proteins surrounding a biconcave or dumbbell-shaped core (Knight et al., 1989). The
core is enclosed by two lateral bodies (Knight et al., 1989) whose functions are
unknown. The double-stranded, linear poxviral DNA is found within the core unit.

Figure 5. Tanapox Virus. Electron micrograph of purified tanapox virus stained
with uranyl acetate. Bar = 100nm
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Viral<:.:::Genome Structure and Organization
TPV is a double-stranded, linear DNA virus. The genome of TPV, like that of
YLDV (Knight et al., 1989) and Yaba virus (Kilpatrick and Rouhandeh, 1985,
Kilpatrick and Rouhandeh, 1987), is approximately 145 kbp as determined by
restriction endonuclease analysis (Knight et al., 1989). Although extensive cross
hybridization has been documented between the three viruses (Knight et al., 1989),
the TPV genome is distinct from Yaba virus and YLDV. ITRs probably exist at the
two ends of the genome since they have been reported in most other poxviruses
(reviewed in Moss, 1996). Proximal to the ITR region, terminal hairpin loops have
been identified (Kilpatrick and Rouhandeh, 1987, Knight et al., 1989). These genes
are variable in poxviruses and may contain genes that are nonessential for replication
in tissue culture (Kotwal and Moss, 19�8a, Perkus et al., 1991). The terminal regions
may therefore also contain numerous genes encoding many potentially novel proteins.
About 17% of the TPV genome has been cloned (Neering, masters thesis,
1993). TPV Pstl digested DNA fragments: F (9.0 kbp), H (6.6 kbp), J (5.1 kbp), L
(2.1 kbp), M (1.4 kbp), and N (1.1 kbp), were successfully shotgun cloned into pUC
19. The Pstl-L fragment was completely sequenced, predicted amino acids and
putative open reading frames (ORFs) analyzed by Neering (1993). Intelligenetics
analyses revealed 37 complete ORFs and 1 partial ORF within this fragment.
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Biology
Downie et al. (1964) first recovered TPV from human skin lesions and
cultured the virus in vervet-monkey kidney cells. TPV has since also been
successfully cultured in primary human amnion, human embryo lung cells (WI-38),
human thyroid cells, vervet monkey kidney cells (BSC-1), patas monkey cells,
(Downie et al., 1971), embryonic rhesus monkey kidney cells (EMK) (Espana et al.,
1971), CV-1 African green monkey kidney cells (Knight et al., 1989), owl monkey
kidney (OMK) (Essani et al., 1994), and Vero cells (Downie and Espana, 1972). The
virus cannot be cultured in non-primate cell lines. No cytopathic changes were seen
in tissue cultures of chick embryo fibroblasts, primary rabbit kidney, or primary
cultures of bovine embryo kidney (Downie et al., 1971) infected with TPV. Another
interesting aspect of TPV is that unlike other poxviruses, TPV does not produce
pocks on chick chorioallantoic membrane (Downie et al., 1971).
Host Range
Monkeys are the only laboratory animals proven susceptible to TPV infection.
Downie et al. (1971) could not transmit TPV disease to a calf, a lamb, young pigs, a
goat, guinea pigs, mice or rabbits. No neutralizing antibodies were detected in sera
from any of these animals either. However, the same virus suspension (4xl06 ffu/ml
titer) used for inoculum of the above animals did produce papules at the site of
inoculum in 2 rhesus monkeys and 2 vervet monkeys. Neutralizing antibodies were
detected in the sera of the monkeys (Dowaje et al., 1971). In studies on a human
volunteer, vaccinated against smallpox, nodules were seen at the sites of intradermal
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injections and a pock-like lesion with a 1cm diameter was seen at the site of
scarification by day 7 (Downie et al., 1971).

Poxviral particles were found upon

electron microscopy examination. No neutralizing antibodies were found in the sera
of the human volunteer. These studies demonstrate the restricted range of hosts for
TPV to be either man or monkey.
Cytopathic Effect on Host Cell
Cytopathic changes resulting from TPV infection are seen 10 days after TPV
inoculation in primary human thyroid cells (Downie et al., 1971) and BSC-1 cells
(Downie and Espana, 1972), and 5-6 days after inoculation in Vero cells (Downie et
al., 1971). This is slightly faster than in Yaba virus infected cells where plaques

cannot be detected until at least 10-12 days (Yohn et al., 1966). Generally, cytopathic
changes of TPV include increased granulation of the cytoplasm, rounding up of cells,
and eventual destruction of the cell monolayers as viral infection proceeds.
According to studies using electron microscopy by Espana et al. (1971), it was also
found that TPV causes "focal lesions" characterized by enlargement of the nuclei of
infected cells and more densely staining nucleoli. Nicholas and McNulty (1968) also
noted nuclear vacuoles after 6 days of TPV infection. The significance of these
nuclear vacuoles however is not known and has not been noted in Yaba or
monkeypox virus infected cells (Nicholas and McNulty, 1968). The cytoplasm of
TPV infected cells contained many poxvirus particles in different stages of
development in viral factories (Espana et al., 1971). Espana et al. (1971) identified
two types of cytoplasmic inclusions. The first was approximately lµm in diameter,

composed of finely granular material and viral membranes with spicules were
observed. The second type of inclusion was larger and contained more coarsely
granulated materials. Espana et al. (1971) postulated that the first inclusion appeared
to be the site of virus membrane manufacture and the second inclusion area the site of
the development of the nucleoids, presumably DNA
Plaque assays using BSC-1 by Nicholas and McNulty (1968) show that
plaques are less than Imm in diameter and do not appear until 4-6 days post infection.
Knight et al., (1989) found similar sizes in plaques seen in CV-1 cell monolayers.
Cells and medium sonicated to release virus, at the time of maximum CPE, yielded
105-106 pfu/ml cells. Concentration and purification of the virus using sucrose
density gradients increased the total virus numbers to 107-108 pfu/ml (Nicholas and
McNulty, 1968).
Pathogenesis
In humans, TPV causes mild, self-limiting disease characterized by swelling
of regional lymph nodes, transient fever, headaches, and pock-like skin lesions
(Downie et al., 1971). TPV induced skin lesions are similar to the pock-like lesions
of smallpox but are larger and develop slower (Downie et al., 1971). The pock-like
lesions are initially nodular, resembling an insect bite, and gradually enlarge to form
papules with a maximum diameter of about 15mm by the end of the second week.
This is much smaller than the lesions induced by Yaba virus infection, which reach
maximum diameters of 25-45 mm. TPV lesions are benign and do not take on the
appearance of the tumorous masses seen in Yaba virus disease.

There is no
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postulation and only a single lesion is usually seen. Lesions occur primarily on the
upper arm, face, neck, and trunk (Downie et al., 1971). Laboratory investigations of
the lesions show hypertrophy and thickening of the epithelial layers of the skin with
swelling and ballooning of the deeper epithelial cells (McNulty et al., 1968, Downie
et al., 1971). There is little involvement in the underlying dermis as seen in Yaba
virus infection (Bearcroft and Jamieson, 1958). Epithelial cells show �acuolation of
cell nuclei and cytoplasmic inclusion bodies (Downie et al., 1971). In Yaba virus
infection, no nuclear vacuolation has been reported. TPV infection, unlike vaccinia
and variola viruses, shows little inflammatory cell infiltration of the epithelium.
The incubation period in natural human cases is unknown (Jezek et al., 1985)
but the disease lasts from 3 to 4 days with even the most severely affected patients
recovering without complications (Joklik, 1988b). Skin lesions disappear within 6 to
7 weeks. Clinical diagnosis of TPV is made on the basis of the characteristic skin
lesions and is confirmed based on the brick-shaped morphology of the poxvirus under
electron microscopy.
TPV appears to be a zoonosis, but neither the reservoir host nor the mode of
transmission to man is known. Sera collected from several species of monkeys from
various parts of the world including, Malaysia, India, South America, and Africa,
show the presence of neutralizing antibodies to TPV only in those animals from
Africa and Malaysia (Downie, 1974). As with Yaba virus (Bearcroft and Jamieson,
1958, Niven et al., 1961, Ambrus et al., 1969), a biting arthropod vector has been
suggested which may possibly spread the. virus from monkeys to man (Downie et al.,
1971, Manson-Bahr and Downie, 1973).

Growth Kinetics
Viral adsorption assays demonstrate that 76% of TPV adsorbs to OMK cell
monolayers one hour post inoculation at 10 plaque fonning units (pfu)/cell
(Mediratta, masters thesis, 1997). Using plaque assays, the single step growth curve
for TPV was determined by Mediratta and Essani (1999). The eclipse period for
TPV, which is the time from adsorption until the first appearance of intracellular
infectious viral progeny (Joklik, 1966), was shown to last for 24 h.p.i at a m.o.i. of 10
pfu/cell. The average infectious virus recovered during the eclipse period was 0.18%
and 0.008%. The latent phase, or the time from adsorption until the appearance of
first extracellular infectious mature virion, was detennined to last until 36 h.p.i. at 10
pfu/cell. At 10 pfu/cell, maximal intracellular and extracellular viral titers were seen
at 96 h.p.i. The yield of virus per cell at 10 pfu/cell is 17. One important feature of
poxviral multiplication is that most mature viral progeny is retained within the host
cell. This was confirmed in experiments done by Mediratta and Essani (1999), where
it was found that at 96 h.p.i., approximately 78% of the mature progeny was retained
intracellularly and only 18% of the total viral progeny was present in the supernatant.
In addition, the yield ofTPV per cell obtained at 10 pfu/cell was found to be 18 times
lower than for vaccinia virus (Mediratta and Essani, 1999).
Anti-Cytokine Activity in Supernatant From TPV Infected cells
Electrophoretic examination of supernatant from TPV infected cells revealed
the presence of a single 38 kDa protein that was not found in mock or non-infected
cell supernatant (Essani et al., 1994). This 38 kDa protein was detennined to be an
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3

early polypeptide expressed pnor to viral DNA synthesis. Based on H-Nacetylglucosamine labeling, the protein was shown to be glycosylated.

Binding

studies using concentrated supernatant from TPV infected cells revealed that the
protein bound to human (h)IFN-y, hIL-2, and hIL-5 but not to hIL-1, hIL-8, or hIL10.

Using an assay based on 3H-thymidine uptake, the protein was shown to

biologically inactivate hIL-2 and IL-5. Supernatant from mock infected cells did not
effect thymidine incorporation. The inactivation of IFN-y was further demonstrated
by measuring the reduction in plaque formation in infected cell monolayers. This was
one of the first virally encoded proteins shown to have multiple anti-cytokine activity
binding and neutralizing 3 important cytokines.
Conclusions
To date there is little known about TPV. The viral genome encodes many
genes, both essential and non-essential, which could potentially unlock many answers
to the immune response and virus evasion. Since TPV is similar to smallpox virus
but with greatly reduced virulence, it provides an ideal model to study virus-host
interactions.
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MATERIALS AND METHODS
Cells and Virus
Owl monkey kidney (OMK) cells (American Type Culture Collection,
Rockville, MD) were grown in modified Earle's medium (MEM) supplemented with
10% (v/v) newborn calf serum (NBCS) (Life Technologies, Grand Island, NY), 2mM
L-glutamine, and antibiotics (100units/ml penicillin G sodium, 100µg/ml
streptomycin sulfate, 0.25µg/ml amphotericin B) (Life Technologies)[growth
medium]. Cells were maintained in MEM supplemented with 2% (v/v) NBCS, 2mM
L-glutamine, and antibiotics (maintenance medium). Primary human umbilical vein
endothelial cells (HUVEC) (Clonetics, Walkersville, MD) were cultured in
endothelial cell basal medium (EBM) supplemented with human (h) epidermal
growth factor ( lOµg/ml), hydrocortisone (lmg/ml), GA-1000 (50mg/ml gentamicin
sulfate and 50µg/ml amphotericin-B), bovine brain extract, and 2% (v/v) fetal bovine
serum (FBS) (Clonetics). TPV (American Type Culture Collection) was cultivated at
37°C in OMK cell monolayers. Infected cells were maintained in maintenance
medium and incubated for 10-14 days at 37°C with 5% CO2. Infected cells were
harvested and concentrated 100-fold initially by centrifugation (Damon IEC PR-600
centrifuge) at 500 x g for 30 minutes followed by ultra-centrifugation (Beckman

37

38
Optima XL-lO0K ultracentrifuge; Ti-45 fixed angle rotor) at 85,000 x g for 1 hour.
The pellet was resuspended in maintenance medium to a final concentration of I 00X
and quantitated by plaque assay (Essani, 1982). Briefly, OMK cell monolayers
grown in 6-well plates were infected with 200µ1 each of serial ten-fold dilutions of
100X TPV. Each dilution was plated in duplicate. · Virus was adsorbed at room
temperature for 1 hour on a rocker table. Following adsorption, 2.5ml of overlay
medium [maintenance medium with 0.5% methyl cellulose (4000 centipoises) (Fisher
Scientific, Pittsburgh, PA)] was added to each well and plates incubated at 37° C with
5% CO2 for 7-10 days or until viral plaques were visible. Medium was aspirated

carefully and 1ml of 0.1% crystal violet and 10% formaldehyde in deionized water
was added to each well to fix and stain the cell monolayers for 30 minutes. Plates
were then rinsed and allowed to dry. Plaques were quantified to determine pfu/ml.
Virus Purification
Twenty-five 150cm2 flasks, of TPV infected OMK cell monolayers, were
scraped and pelleted at 85,000 x g for 1 hour. The cell pellet was resuspended in 30ml
of lOmM Tris-HCI (pH 8.0) and placed in a dounce homogenizer. The suspension
was adjusted to 10µg/ml deoxyribonuclease I (Boehringer Mannheim, Indianapolis,
IN) and IOU/ml ribonuclease A (Sigma Biosciences, St. Louis, MO). The mixture
was homogenized with 15 strokes, incubated for 20 minutes in a 37° C water bath, and
dounced another 15 strokes. The virus preparation was further homogenized with 15
strokes after adjusting to 0.5mg/ml of trypsin, lOmM EDTA. Following a 15 minute
incubation in a 37° C water bath, the mixture was homogenized with 10 additional
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strokes. The final virus preparation was loaded onto a 40% sucrose cushion and
centrifuged at 30,000 x g for 97 minutes to remove cellular debris. The resulting
virus pellet was resuspended in 2ml lOmM Tris-HCl (pH 8.0). The viral suspension
was incubated for 30 minutes at 37°C after adjusting to 50µg/ml of trypsin. The virus
preparation was homogenized with a final 10 strokes and the virus mixture then
loaded, through a 13-gauge needle, onto a freshly prepared 20-40% sucrose gradient
to separate enveloped and non-enveloped virus particles. The purified virus bands
were collected and centrifuged at 30,000 x g for 1 hour. The virus pellet was
resuspened in 500µ1 of lOmM Tris-HCl (pH 8.0) and stored at -20°C.
Supernatant Preparation
Confluent OMK cells grown in 60mm dishes were infected with TPV (50
pfu/cell) and adsorbed for 1 hour at room temperature. Maintenance medium was
added and cells were incubated for 6 hours at 37°C. At 6 hours-post infection, cell
monolayers were washed 3X with serum-free maintenance medium. Cells were
further incubated for 18 hours at 37°C. Supernatant from TPV infected cells was
collected, initially centrifuged for 30 minutes (500 x g, Damon, IEC PR-6000
centrifuge), followed by 1 hour centrifugation at 85,000 x g; and then dialyzed against
deionized water at 4°C. When necessary the supernatant was lyophilized,
reconstituted with maintenance medium, and filter sterilized with a 0.22µm filter
(Gelman Sciences, Ann Arbor, MI). Mock supernatant was collected from uninfected
OMK cells and prepared in an identical manner.

When necessary, cells were
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radiolabeled

with

50µCi/ml
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{ S]methionine

(1142Ci/mmol

from

ICN

Pharmaceuticals, Inc., Costa Mesa, CA) 2-18 hours post-infection.
Preparation and Analysis of DNA
Preparation of TPV Genomic DNA
TPV genomic DNA was isolated by the proteinase K/sodium dodecyl sulfate
(SDS)/phenol extraction method (Ausubel et al., 1992). Briefly, purified virus was
mixed with 1% SDS, 200µg/ml proteinase K (Life Technologies), 3mM
mercaptoethanol and then incubated for 48 hours in a 37°C water bath. Proteinase K
was added in increments over the incubation period to a final concentration of
200µg/ml. Following incubation, an equal volume of phenol/chloroform/isoamyl
alcohol (25:24:1) was added, the sample mixed gently, and then centrifuged for 5
minutes in a Brinkman 5415C centrifuge (14,000 x g). The aqueous layer was
collected and the procedure was repeated twice. To the recovered aqueous layer, 1/10
volume of 3M sodium acetate, pH 5.2 was added and mixed gently. Two volumes of
100% ethanol was added, mixed, and DNA precipitated at -20°C for 30 minutes.
Resulting DNA was pelleted by centrifugation (14,000 x g) and washed in 70%
ethanol. The DNA pellet was air dried and then in suspended 50 µl in sterile
deionized water.
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Restriction Analysis of DNA
Restriction endonucleases and their appropriate buffers were obtained from
Genosys Biotechnologies, Inc., (The Woodlands, TX) or Life Technologies.
Digestions, using 5U of enzyme per l µg of DNA, were performed according to
manufacturer's specifications for each enzyme. The reaction volumes varied
according to DNA concentrations. All reactions were incubated at 37°C for 12-18
hours. Reactions were terminated by the addition of lX stop solution (0.5M EDTA,
65% sucrose, 0.2% bromophenol blue, and 0.2% xylenecyanol). For the generation
of blunt-ended DNA, Smal restriction endonuclease was used under the following
conditions: 5U of Smal (20mM Tris-HCl, pH 7.5, l mM Na2EDTA, 7mM 2mercaptoethanol, 500µg/ml BSA, 50% (v/v) glycerol) per µg DNA, lX REact 4
(20mM Tris-HCl, pH 7.4, 5mM MgCh, 50mM KCl) in a total volume of 10µ1 with
sterile deionized water.
Dephosphorylation of pUC19
Dephosphorylation of pUC19 was accomplished using calf intestinal alkaline
phosphatase (CIAP)(Life Technologies). Briefly, l µl of CIAP (27U/µl) (25mMTris
HCl, pH 7.6, l mM MgCh, 0. l mM ZnCh, 50% (v/v) glycerol) was added to 3-5µg of
DNA along with 1µ1 lOX CIAP dephosphorylation buffer (50mM Tris-HCI, pH 8.5,
O . l mM EDTA) and brought up to 10µ1 with deionized water. The mixture was
incubated at 37° C for 15 minutes then at 56°C for an additional 15 minutes. An
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additional 1µl of CIAP was added and the dephosphorylation reaction reincubated as
stated above. The reaction was terminated by heating at 75 °C for 10 minutes.
SI Nuclease Digestion of Hairpins
To clone the TPV Pstl terminal genomic DNA fragments, the covalently
linked terminal ends (hairpins) had to be cleaved. Pstl digested fragments of TPV
DNA were treated with SI nuclease (Life Technologies) following manufacturer's
directions. Briefly, 5µg of Pstl digested TPV DNA was mixed with lµl SI nuclease
(99.1 U/µl) (20mM Tris-HCI, pH 7.5, 0. lmM zinc acetate, 50mM NaCl, 50% (v/v)
glycerol), 1µ1 lOX SI nuclease buffer (300mM sodium acetate, pH 4.6, lOmM zinc
acetate, 50% (v/v) glycerol), 0.83µ13M NaCl and brought up to 10µ1using deionized
water and incubated at 37°C for 30 minutes. The reaction was terminated by adding
0.5µ1 of 0.5M EDTA (25mM). DNA was extracted twice with an equal volume of
phenol:chloroform (1:1), ethanol precipitated, and reconstituted in 5µ1 of deionized
water.
Repair of S1 Digested Ends
The S1 nuclease cleaved TPV DNA ends were repaired with DNA
polymerase I, large (Klenow) fragment (Life Technologies). SI nuclease cleaved
TPV DNA (5µg) was mixed with 1µ1 l OX React 2 (500mM Tris-HCI, pH 8.0,
lO0mM MgCh, 500mM NaCl), 0.5µ1 DNA polymerase I, large (Kienow) fragment
( I OU) (50mM potassium phosphate, pH 7.0, lO0mM KCl, lmM dithiothreitol (DTT),
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50% (v/v) glycerol) and deionized water to bring total volume to 10µ1. The mixture
was incubated at 15°C for 1 hour and the reaction terminated with the addition of
0.5µ1 of 0.5M EDTA (25mM).
Blunt-End Ligation
Dephosphorylated, Smal cut pUC19 was desalted and concentrated using the
QIAEX II gel extraction kit (Qiagen Inc, Valencia, CA) following manufacturer's
suggestions.

Cleaned, dephosphorylated Smal cut pUC19 and blunt-ended Pstl

digested TPV DNA were ligated using a DNA ligation kit (Sigma Biosciences). In an
Epindorf tube, 1 µl lOX ligation buffer (250mM Tris-HCl, pH 7.8, lO0mM MgCli,
l 0mM DTT), 60fmol (53ng) vector (Smal cut, dephosphorylated pUC 19), 180fmol
(306ng) insert (blunt-ended TPV DNA fragments), l µl T4 ligase (lU)(lOmM Tris
HCl, pH 7.5, 50mM KCl, l mM DTT, 50% (v/v) glycerol), 12% PEG, and nuclease
free water to bring volume up to,10µ1 were mixed gently and incubated at 14°C for
14-18 hours. The reaction was terminated by heating to 65°C for 10 minutes.
Transformation
Transformation of DH5a.-MCR competent cells (Life Technologies) was
performed by adding 5µ1 of ligation mixture to 20µ1 of competent cells and
incubating at 4°C for 30 minutes. The mixture was then heat shocked for 45 seconds
in a 42°C water bath. The tubes were removed from the water bath and then returned
to 4°C for 2 minutes. SOC medium (2% tryptone, 0.5% yeast extract, lOmM NaCl,
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2.5mM KCI, lOmM MgCli•6H2O, and 20mM glucose) was added to the mixture and
incubated in a 37°C shaker for 1 hour at 225rpm. The suspension was then plated out
in triplicate, using 20µ1, 50µ1, and 100µ1 of the suspension, on LB agar plates (10g/L
tryptone, 5g/L yeast extract, 5g/L NaCl, 10g/L dextrose, and 15g/L agarose)
containing 50µg/ml of ampicillin. The plates were incubated at 37°C overnight.
Isolation of Plasmid DNA
Plasmid DNA was prepared according to the alkaline lysis method (modified
from Ausebel et al., 1992). Bacterial clones were grown in LB broth (10g/L tryptone,
5g/L yeast extract, 5g/L NaCl, and 10g/L dextrose) containing 50µg/ml of ampicillin
and incubated overnight in a 37°C shaker incubator (200rpm). Cells were pelleted by
centrifugation at 700 x g (Damon IEC PR-6000 centrifuge), washed in IX PBS, and
repelleted at the same speed. Cell pellets were suspended in lysis buffer (25mM Tris
HCI pH 8.0, lOmM EDTA, and 50mM glucose) and transferred to 1.5ml
microcentrifuge tubes. Lysis buffer with lysozyme (lOmg/ml) (Sigma Biosciences)
was added to disrupt bacterial cell walls and incubated on ice for 5 minutes. Alkali
SDS (0.2N NaOH and 1% SDS) was added, tubes inverted IOX, and further
incubated on ice for 5 minutes. 3M sodium acetate (400µ1) was added to neutralize
the alkali solution and to precipitate proteins and large DNA Cells were centrifuged
at high speed (10,000 x g), incubated on ice for 15 minutes and then recentrifuged.
The supernatant was removed, isopropanol added and then placed at -70°C for 30
minutes to precipitate plasmid DNA Plasmid DNA was pelleted at 4°C by
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centrifugation (10,000 x g), and resuspened in deionized water. Proteins were
separated by phenol-chlorofonn extraction and the aqueous layer collected. To
precipitate RNA, 200µ1 ammonium acetate (7M) was added to the aqueous layer,
incubated on ice for 10 minutes, and RNA pelleted by centrifugation (10,000 x g).
The supernatant was collected, 100% ethanol added, and incubated on dry ice for 10
minutes to precipitate plasmids. Plasmid DNA was pelleted and resuspended in 0.3M
sodium acetate. Ethanol (100%) was once again added to precipitate plasmid and
incubated on dry ice for 10 minutes. The plasmid DNA pellet was resuspended in
deionized water and stored at -20°C.
Resolution and Recovery of DNA Fragments
Agarose Gel Electrophoresis
Agarose gels (0.7%) were prepared by dissolving agarose in lX TBE buffer
(89mM Tris, 89mM boric acid, 2mM EDTA, pH 8.0) by heating to a 100°C.
Ethidium bromide (1.0µg/ml) was added directly to the agarose solution and the gel
was then poured and allowed to solidify. DNA samples were prepared with IOX
loading buffer (25% Ficoll 400, 0.25% bromophenol blue, 0.25% xylene cyanol).
Samples were electrophoresed at 50 V for 2-6 hours. Electrophoresis was in lX TBE
buffer, pH 8.0. DNA markers, 11. Hindlll and/or �XI 74 Haelll (Life Technologies)
were run alongside samples to estimate molecular sizes of DNA fragments.
Following electrophoresis, gels were illuminated on an UV light source (Fotodyne
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Foto/Prep UV transilluminator, Hartland, WI) and photographed with a Fotodyne
FCR-10 camera using a red filter and Polaroid type 667 film.
Recovery of DNA Fragments
DNA fragments were recovered from 0.7% agarose gels using the QIAEX II
gel extraction kit (Qiagen, Inc.) following manufacturer's suggestions. Briefly, the
DNA band was excised from the gel, incubated at 50°C for 10 minutes in 3 volumes
of buffer QXI and 10µ1-30µ1 of QIAEX II to solubilize the agarose and bind DNA to
QIAEX II silica particles. The mixture was centrifuged for 30 seconds to pellet DNA
bound silica beads. The pellet was washed in 80% ethanol solution twice, and DNA
eluted in 20µ1 of sterile deionized water.
Analysis of DNA by Blotting and Hybridization
Southern Hybridization
DNA was digested with restriction endonuclease and electrophoresed through
a 0.7% agarose gel containing 1 µg/ml ethidium bromide. The gel-fractionated DNA
was photographed alongside a ruler over a gel illuminator (Fotodyne Foto/Prep UV
transilluminator). The gel was denatured in I.SM NaCl and 0.5M NaOH for 1 hour at
room temperature and then neutralized for another hour in IM Tris-HCI (pH 8.0) and
1.5M NaCl. The DNA fragments were transferred to a nylon membrane (ICN
Pharmaceuticals, Inc.) using standard methods as described in Maniatis et al. (1989)
modified from Southern (1975). The membrane was soaked in 6X SSC (3M NaCl,
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0.3M sodium citrate, pH 7.0), allowed to air dry at room temperature and then UV
crosslinked for 1 minute or baked at 80°C for 2 hours. TPV probes were designed
from the N-terminus amino acid sequence of the isolated 38 kDa TPV protein
(ITLKY-YTVTLKDNGLYDG FY-HYN-QL) (see Table 2). TPV probes were 5'
V

end labeled with [y-32P ATP] (4500Ci/mmol) (ICN Pharmaceutical, Inc.) as described
Table 2
Hybridization Probes
Probe
TPV-3
TPV-5
TPV-6
MT2

Size
18mer
24mer
24mer
1.1 kbp

Tm
Probe Sequence
°
5'-TAT-GAT-GGT-GTT-TTT-TAT-3'
41 c
57.6°C 5'-GGA AAG TGT AAA GAC AAC GAA TAC-3'
59.3 °C 5'-GCT-TGT-CTA-AGT-TGT-AAC-GGA-AGA-3'
(Upton et al.,1991)

by Maniatis et al. (1982). Briefly, 50pmol of DNA was mixed with 20U T4
polynucleotide kinase (50% glycerol (v/v), 50mM Tris-HCI, pH 7.6, 25mM KCI,
5mM OTT, O. lµM ATP, 0.2mg/ml BSA) (Life Technologies), IX forward reaction
buffer (350mM Tris-HCI, pH 7.6, 50mM MgCh, 500mM KCI, 5mM 2mercaptoethanol), and 150µCi [y-32P ATP] (4500Ci/mmol), and then incubated at
37°C for lhour. Probes were purified using the Nensorb 20 nucleic acid purification
cartridge (NEN Life Science Products, Boston, MA) or Probe Quant G-50
microcolumns (Amersham Pharmacia Biotech, Piscataway, NJ) as directed by
manufacturer. Nensorb 20 cartridges were pre-equilibrated with reagent A (O. IM
Tris-HCI, lOmM triethylamine, lmM disodium EDTA, pH 7.7). Four hundred
microliters of reagent A was added to the radiolabeled probe mixture and then passed
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through the column. The column was washed with 3ml reagent A and 3ml deionized
water, respectively. The probe was eluted with reagent B (50% methanol in water), at
a flow rate of 1 drop/second, and counts detected on a scintillation counter to
determine fractions containing radiolabeled nucleic acid.

Probe Quant G-50

microcolumns were prepared by initially vortexing to resuspend the resin bed and
then pre-spinning the column for 60 seconds at 735 x g. The radiolabeled probe
mixture was slowly added to the column and then centrifuged at 735 x g for 2
minutes. The purified sample was collected and counts detected on a scintillation
counter.
The pMTN-6 vector (Schreiber and McFadden, 1994 ) containing the MT2
gene (Upton et al., 1991) was kindly supplied by Xiao-Ming Xu. The MT2 insert
was excised from the pMTN-6 vector using restriction endonucleases, Hindlll and
Pstl. The 1.1 kbp fragment was gel purified as described previously and radiolabeled

with [a,-32P dCTP] using the random prime DNA labeling system (Life
Technologies). Briefly, 25ng of DNA was dissolved in 10µ1 of distilled water,
denatured by boiling for 5 minutes and then immediately placed on ice. To the DNA,
15µ1 random prime buffer mixture (0.67M HEPES, 0.17M Tris-HCl, 17mM MgCh,
33mM

2-mercaptoethanol,

1.33mglml

BSA,

l8(OD260)units/ml

oligodeoxyribonucleotide primers (hexamers), pH 6.8), 5µ1 (50µCi) [a-32P dCTP]
(3000Ci/mmol), 2µ1 of each dATP, dGTP, and dTTP solution (0.5mM), l µl (3U)
DNA polymerase, large fragment (Kienow fragment) (50mM potassium 'phosphate
buffer (pH 7.0), IO0mM KCI, l mM DTT, 50% (v/v) glycerol) and distilled water to
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49µ1 was added on ice. The mixture was incubated at room temperature for 1-3 hours
and 5µ1 stop solution (0.5M EDTA, pH 8.0) was added.
Varied conditions were used for hybridization depending on the probe ( see
Table 3). Method 1 was utilized for TPV-probe 3 (Genosys Biotechnologies, Inc.),
method 2 for TPV-probe 5 (MWG Biotech, High Point, NC), method 3 for TPV
probe 5 (MWG Biotech), and method 4 for the MT2 probe. Pre-hybridization
solution was composed of 6X SSC (0.3M NaCl, 0.03M sodium citra�e, pH 7.0), 5X
Denhardt's solution [1% each BSA, Ficoll, PVP (Sigma Biosciences)], 0.5% SDS,
and O. lmg/ml salmon testes DNA (Sigma Biosciences). Washed blots were placed
on film and stored at -80°C. Films of blots hybridized with TPV-probes were
developed after 1 week. Films of MT2 probed blots were developed after 15 hours,
because of higher counts detected by the Geiger counter, and the blots washed further
at increasing temperatures ranging from 35°C up to 68° C.
Table 3
Hybridization Conditions
Method

Hybridization
PreWash conditions
hybridization
30° C, 4 hours 30°C, overnight 4 washes in 2X SSC and 0.1% SOS at 35° C, 15
minutes/wash
45 °C, overnight 45 °C, overnight 4 washes in 2X SSC and 0.1% SOS at 30°C, 15
minutes/wash
30° C, 2 hours 30° C, 24 hours 4 washes in 2X SSC and 0.1% SOS at 25 °C, 15 minutes/
wash
25 °C, 1 hour 25° C, overnight 4 washes in 2X SSC and 0.1% SOS at 25 °C-68° C, 15
minutes/wash
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DNA Sequencing
Polymerase Chain Reaction (PCR)
PCR was carried out to amplify smaller regions from the 5.0 kbp TPV Pstl-J
fragment for sequencing. All reagents were obtained from Life Technologies. PCR
products, ranging from 600 bp to 2 kbp, were generated from 0.5µg plasmid DNA
using 1.75U Taq DNA polymerase, lX PCR buffer (20mM Tris-HCL, pH 8.4, 50mM
KCL), 1.5mM MgCh, 0.2mM dNTPs, and 25pM each primer in a 50µ1 reaction.
Thirty cycles of PCR amplification were performed as follows: denaturation 94°C for
30 seconds, annealing 45° C for 1 minute, extension 68°C for 2 minutes. Amplified
products were analyzed by agarose gel electrophoresis and visualized by ethidium
bromide staining.
PCR products were dried down in a speed vacuum and resuspended in 10µ1 of
water. To separate nonspecifically amplified primers, unincorporated primers, or
remaining plasmid DNA, PCR products were electrophoresed on a 0.7% agarose gel
in TBE buffer. DNA fragments were extracted using the QIAEX II gel extraction kit
(Qiagen, Inc.) as described previously.
Cycle Seguencing and Dye Terminator Removal
Samples were cycle-sequenced using an ABI Prism big dye terminator cycle
sequencing ready kit (Perkin Elmer, Foster City, CA). Template DNA (60ng), 3pmol
primer, 3µ1 premix buffer, were mixed to a total reaction volume of 20µ1.
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Unincorporated dye terminators were removed using Centri-Sep columns (Princeton
Separations, Inc., Adelphia, NJ) as directed by manufacture. Briefly, the matrix was
prepared by hydrating the column with water, air bubbles removed, and the column
was allowed to settle for 30 minutes. Interstitial fluid was drained from the column
by gravitational flow, and then any remaining traces of fluid removed by
centrifugation at 750 x g for 2 minutes. Sample was carefully added to the center of
the column matrix, centrifuged at 750 x g for 2 minutes, and DNA collected.
Dideoxy Seguencing Method
Sequencing reaction products were analyzed using an ABI Prism 310 DNA
sequencer (Perkin Elmer) or sent out to Biosynthesis (Lewisville, TX) for analysis.
The nucleotide sequence for both strands was determined. The universal Ml3/pUC
forward (5'-CGC-CAG-GGT-TTT-CCC-AGT-CAC-GAC-3') and reverse primers
(5'-AGC-GGA-TAA-CAA-TTT-CAC-ACA-GGA-3') were used to obtain the initial
sequence.

From this, custom 18- to 24-mer oligodeoxyribonucleotides were

synthesized usmg standard chemistries (Biosynthesis and Life Technologies) to
primer walk the remaining fragment.
DNA Seguence Analysis
The Auto Assembler DNA Sequence Assembly software, version 2.0 (PE
Applied Biosystems, Foster, CA) was utilized to assemble and edit DNA sequences.
Searches for DNA sequence homology were performed using the BLASTX (Altschul
et al., 1990) program available at the National Center for Biotechnology Information
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(NCBI) website (www.ncbi.nlm.nih.gov). The ORF FINDER program at the NCBI
web site (www.ncbi.nlm.nih.gov/gorf/orfig.cgi) was used to determine probable
ORFs . Multiple alignment and comparison of DNA and protein sequences was
achieved using the Sequence Navigator software (PE Applied Biosystems).
Preparation and Analysis of RNA
Preparation of Cytoplasmic RNA
The supernatant from either mock infected cells or TPV infected cells was
mixed with TNF-a (50 units/ml), incubated for 1 hour at 4°C, and then added to
HUVEC monolayers. The cell monolayers were incubated for 4 hours at 37°C. Total
c�llular RNA was extracted using acid guanidinium thiocyanate-phenol-chloroform
(Chomczynski and Sacchi, 1987). Briefly, Trizol (Life Technologies) was added to
cell monolayers and placed on a shaker for 10 minutes. One hundred microliters of
chloroform per 1ml of Trizol reagent was added, samples vortexed vigorously, and
then incubated on ice for 15 minutes.

The aqueous phase was collected and

isopropanol added to precipitate the RNA The samples were centrifuged at high
speed (14,000 x g) for 20 minutes at 4°C. One ml of 70% ethanol was added to wash
the RNA pellet and samples were recentrifuged at high speed for 10 minutes at room
temperature.

The pellets were dried in a 37°C incubator for 10 minutes and

suspended in l mM EDTA in RNAse-free water.
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Northern Blot Analysis
RNA (5µg) was electrophoresed through 1% fonnaldehyde-agarose gel
containing lµg/ml ethidium bromide. The gel-fractionated RNA was transferred to
nitrocellulose membranes (Southern, 1975) and immobilized by UV irradiation. The
blots were pre-hybridized for 2 hours in Rapid-hyb buffer (Amersham Int., Arlington
Heights, IL) and hybridized overnight at 65°C with [cx32-P dATP] (3000Ci/mmol)
(Amersham Int.) radiolabeled cDNA probes specific for ICAM-1, E-selectin, VCAM1, or G3PDH. The blots were washed in 2X SSC (0.3M NaCl, 0.03M sodium citrate,
pH 7.0) containing 0.5% SDS for 15 minutes, followed by washes in 0.4X SSC with
0.1% SDS for 30 minutes, and 0.5X SSC for 1-2 minutes respectively. The washed
blots were placed on film at -80°C.

32

P-labeled DNA probes were essentially

generated by random primer oligonucleotide procedure as described (Feinberg and
Vogelstein, 1983). The ICAM-1 probe was an EcoR I fragment of human cDNA
(Staunton et al., 1988), the E-selectin probe was a 1.53kb EcoR I fragment of human
cDNA (Bevilacqua et al., 1989), and the VCAM-1 probe was a Hind 111-Xho I
fragment of the human cDNA consisting of nucleotides 132-1814 (Osborn et al.,
1989).
DNA-Protein Interactions
Preparation of Nuclear and Cytoplasmic Extracts
Cells were washed quickly with 1ml of trypsin and then removed with the
further addition of 2ml of trypsin left on for 3-5 minutes. Cells were collected,
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centrifuged, suspended in buffer A (l0mM HEPES, pH 7.9, 1.5mM MgCb, lOmM
KCl, 0.1% NP-40, and 0.5mM DTT).

After recentrifugation, the cells were

resuspended in 80µ1 buffer A containing 0.1% Triton X-100 by gently pipetting.
After incubation at 4°C for 10 minutes, the homogenate was centrifuged and the
nuclear pellet washed in 40µ1 of buffer C (20mM HEPES, pH 7.9, 0.42M NaCl, 25%
(v/v) glycerol, 1.5mM MgCb, and 0.2mM EDTA). This suspension was incubated
on ice for 30 minutes and then centrifuged at 20,000 x g for 20 minutes. The
resulting supernatant was stored at -70°C as nuclear extract.
Gel Mobility Shift Assay
The supernatant from either mock infected cells or TPV infected cells was
mixed with TNF-a (50 units/ml), incubated for 1 hour at 4 °C, and then added to
HUVEC monolayers. Cells were harvested at 20 minutes following stimulation, and
nuclear fractions prepared as described above. Total protein concentration was
determined using bicinchoninic acid (BCA) assay (Pierce, Rockford, IL) using BSA
as the standard. Double-stranded (ds) oligonucleotide containing a consensus NF-KB
recognition sequence (Promega, Madison, WI) was end-labeled with T4
polynucleotide kinase in the presence of [y32-P ATP] (>7,000Ci/mmol) (Amersham
Int.) (Maniatis et al., 1982). For the assay, lOµg of nuclear protein were incubated
with O. lpmol of

[

32

P] radiolabeled ds oligonucleotide in a binding buffer (12mM

HEPES, 4mM Tris-HCl, 60mM KCl, lmM DTT, lµg poly(dI-dC), pH 7.9) for 30
minutes at room temperature (Bennett et al., 1996). Competition experiments were
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conducted using 50-fold molar excess of the competing unlabeled ds oligonucleotide
together with the labeled one. Super shift assays were conducted using antibodies to
the subunits of NF-KB.

Samples were loaded on a 5% IX Tris-glycine

polyacrylamide gel (50mM Tris-Cl, 380mM glycine, 2mM EDTA, pH 8.5).
Following electrophoresis the gel was dried and analyzed by autoradiography.
Analysis and Detection of Proteins
Quantitation of Proteins
Total protein concentration was determined using the bicinchoninic acid
(BCA) assay (Pierce, Rockford, IL) or the Lowry method (1951), using BSA as the
standard.
Electrophoretic Separation of Proteins
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
(Laemmli, 1970) was used to separate proteins based on size. The lower gel was
prepared with lower gel buffer (1.5M Tris-base, 0.4% SDS, pH 8.8), and 11.5%
acrylamide (acrylamide:bisacrylamide ratio, 19:1). Polymerizing agents ammonium
persulfate and TEMED (Life Technologies) were added immediately prior to pouring
the gel. The upper gel was prepared with upper gel buffer (0.5M Tris-base, and 0.4%
SDS, pH 6.8), 4.5% acrylamide (acrylamide:bisacrylamide ratio, 19:1), 30µ1
ammonium persulfate, and 10µ1 TEMED.

The lower gel was first poured and

allowed to polymerize for 1 hour. The upper or stacking gel was then poured on top

of the lower gel and also allowed to polymerize for 1 hour. Samples were prepared
with lOX-dissociation buffer (62.5mM Tris-HCl, pH 6.8, 2.3% SDS, 10% glycerol,
5% 2-mercaptoethanol, 0.001% bromophenol blue) and boiled for 3 minutes before
loading. Samples were electrophoresed at 50 mA in IX running buffer (0.025M Tris
base, 0.192M glycine, and 0.1% SDS) for 4 hours.
Staining Proteins in Gels
After electrophoresis, the gel was placed in staining solution (0.25%
Coomassie brilliant blue, 50% methanol, and 10% acetic acid) at room temperature 4
hours to overnight. The gel was fixed and destained in destaining solution (5%
methanol and 7.5% acetic acid) at room temperature with shaking.
Drying Gels
The destained, fixed gel was washed in deionized water, placed on a piece of
Whatman 3MM paper cut to the size of the gel, and then covered on one side with
plastic wrap. The gel was dried for 2 hours by vacuum and then exposed to Kodak X
Omat autoradiography film (Rochester, NY) overnight at room temperature.
Protein Purification
A TNF-a affinity column was prepared using the Aminolink Plus Coupling
Gel (Pierce) and manufacturer's specifications. Briefly, the column was equilibrated
with 2.5 column volumes of pH IO coupling buffer (O.IM sodium phosphate, 0.15M
NaCl, pH 7.2), 1-2 column volumes of ligand solution (2.5mg TNF-cx/3ml agarose
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dialyzed against coupling buffer) was added, and the column placed on a rocker for 4
hours at 25° C to mix the reaction slurry. The column was allowed to drain and then
washed with 2.5 column volumes of pH 7.2 coupling buffer (O. IM sodium citrate,
0.05M sodium carbonate). One column volume of pH 7.2 coupling buffer and 40µ1
of reducing agent (0.5M sodium cyanoborohydride solution) per 2ml of coupling
buffer were added to the reaction mixture and then placed on a rocker for 4 hours at
room temperature. BCA protein assay was used to determine the amount of ligand
coupled to the gel by the difference in the amount of ligand present before and after
coupling. To block any remaining active sites, the liquid coupling solution was
drained and the gel was washed with 2 column volumes of quenching buffer (lM
Tris-HCI, pH 7.4). Following washing, 1 column volume of the quenching buffer and
0.2 column volumes of reducing solution were added to the column and the column
mixed on a rocker for 30 minutes. Following mixing, the column was drained, and
first washed with at least 10 column volumes of wash solution ( IM NaCl), then
washed twice with 2.5 column volumes of degassed storage solution (0.05% sodium
azide in PBS). The top porous disc was placed into the column with 2.5 column
volume wash and pushed down to Imm of the gel surface. Filter sterilized [35S]
labeled supernatant from TPV infected cells (preparation described above) was
passed through the TNF-a. affinity column. The column was washed with IX PBS
(137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 1.4mM KH2PO4, pH 7.0) until no
radioactivity was detected in the flow through. The TNF-a. binding proteins were
eluted with IM acetic acid, dialyzed overnight at 4°C against several changes of
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deionized water, and lyophilized. Eluted TNF-a binding proteins were reconstituted
in deionized water and analyzed by polyacrylamide gel electrophoresis.
Protein Sequence Analysis
Supernatant from TPV infected cells and mock infected cells (described
above) was lyophilized and reconstituted in serum-free growth medium. Samples
were boiled for 3 minutes, loaded on a 10-20% Tris-Glycine pre-cast gel (10-20%
acrylamide, 2.6% bisacrylamide, pH 8.6) (Novex, San Diego, CA), and run at 120
constant voltage for 2 hours in Tris-Glycine running buffer (29g/L Tris base, 144g/L
glycine, pH 8.3). Low and mid-range markers (Promega) were run alongside samples
for size determination. Following electrophoresis, the gel was equilibrated with two
15 minute washes in buffer C (25mM Tris, 40mM norleucine, pH 9). For each gel, 4
filters (3M from Biorad, Hercules, CA) were equilibrated in buffer C, 2 filters in
buffer B (25mM Tris, pH 10.5), and 3 filters in buffer A (300mM Tris, pH 10.5). A
polyvinyldenefluoride (PVDF) membrane (0.45µM, Millipore Corp. Inc., Bedford,
MA) was dipped in 100% methanol for 10 seconds prior to rinsing for 10 seconds in
water and then equilibrated in buffer C. The blotting sandwich for the gel was
arranged from the positive to the negative electrode as follows: (a) 4 filters in buffer
C, (b) PVDF membrane in buffer C, (c) gel in buffer C, (d) 2 filters in buffer B,
and (e) 3 filters in buffer A The transfer was conducted at 1.5 mA constant current
per centimeter squared PVDF membrane for 55 minutes. After electroblotting, the
blot was stained for visualization in Coomassie blue stain for 15 minutes and then
destained in 10% acetic acid and 50% methanol. The membrane was air-dried. The
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38 kDa protein band was excised from the PVDF membrane and directly sequenced
using N-terminal analysis by automated Edman degradation.
Enzyme Linked Immunosorbent Assay (ELISA)
Prepared supematants from TPV infected cells- and mock infected cells were
pre-incubated with either TNF-a (50 units/ml) or IL-lf3 (0.25ng/ml) for 1 hour at 4°C
and then added to HUVEC monolayers in 96-well tissue culture plates. Cells were
incubated for 4 hours at 37 ° C. Cells were then washed three times with PBS (pH
7.0), fixed with 1% paraformaldehyde in PBS for 15 minutes, and washed again in
PBS, three times. Required primary antibody in PBS (lµg/ml) with 0.1% BSA was
added to each well and cells further incubated for 2 hours at 37°C. Following
incubation, cells were again washed and incubated for 2 hours with alkaline
phosphatase-conjugated goat anti-mouse IgG (Cappel, West Chester, PA) in PBS
with 0.1% BSA

To detect the binding of secondary antibody, p

nitrophenylphosphate (pNPP) alkaline phosphatase substrate (lmg/ml) (Sigma
Biosciences) in diethanolamine solution (IM diethanolamine, 0.5mM MgCh,
0.02g/dl NaN3, pH 9.8) was added. The plates were incubated for 20-40 minutes at
37 °C and then read on an ELISA microplate reader at an OD of 405nm.

RESULTS
Inhibition of CAM Gene Expression
In the inflammatory response, recruitment of leukocytes to sites of injury and
infection is mediated by the expression of adhesion molecule receptors on the surface
of endothelial cells. Specific cell adhesion molecules (CAMs) such as intercellular
adhesion molecule-I (ICAM-1), vascular cell adhesion molecule-I (VCAM-1), or E
selectin are expressed on endothelial cells in response to inflammatory stimuli (Pober
and Cotran, 1991). Cytokines such as TNF-a, IFN-y, and IL-lf3 are known to up
regulate the expression of CAMs. Soluble poxviral homologs of cytokine receptors
have been identified to be secreted from virus infected cells (Shchelkunov et al.,
1993a, Buller and Palumbo, 1991, Smith and Goodwin, 1995, Smith, 1994), which
inhibit the activity of various cytokines crucial to the inflammatory response
including TNF-a and IFN-y. Knowing the anti-cytokine activity of supernatant from
TPV infected cells (Essani et al., 1994), the present study was undertaken to examine
the effects that this supernatant from TPV infected cells could have on the
inflammatory response.

As endothelial cells are closely associated with

inflammation, these cells could be used to examine the effects of supernatant from
TPV infected cells on CAM gene expression. Total RNA was prepared from human
umbilical vein endothelial cells (HUVEC) treated with supernatant from TPV
infected cells pre-incubated with TNF-a. Treatment of HUVEC with TNF-a
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normally induces the expression of E-selecti� ICAM-1, and VCAM-1 genes (Figure
6, lane 2).

The cellular extracts were run on a I% formaldehyde-agarose gel.

Northern blot analyses were performed to measure CAM gene expression. As shown
in Figure 6, RNA isolated from cells treated with supernatant from mock infected
cells showed that TNF-a induced CAM gene expression was unaffected (Figure 6,
lane 3). Levels of expression were equivalent to those of cells treated with TNF-a
alone (Figure 6, lane 2).

These results indicate that mock supernatant is not

interfering with TNF-a induced CAM gene expression. However, cells treated with
supernatant from TPV infected cells (Figure 6, lane 4) showed complete inhibition of
TNF-a. induced CAM gene expression. These results suggest that supernatant from
TPV infected cells is interfering with the transcription of TNF-a induced CAM
genes.
Selective Down-Regulation ofTNF-a Induced CAMs
To explore whether TNF-a induced CAM down-regulation through TPV
infected cell supernatant was selective to TNF-a, HUVEC were exposed to IL-I 13
(0.25ng/ml), also an inducer of CAM expression. HUVEC were stimulated for 4
hours with supernatant samples prepared as described previously. Using quantitative
ELISA to measure CAM expression, we found that supernatant from TPV infected
cells down-regulated TNF-a induced expression of E-selectin (Figure 7B), ICAM-1
(Figure 7D), and VCAM-1 (Figure 7E). Down-regulation ofICAM-1, E-selectin, and
VCAM-1 were comparable to non-stimulatory levels. This was not seen with mock
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Figure 6. Inhibition of CAM Gene Expression by Supernatant From TPV Infected
Cells.
Total RNA was isolated and electrophoresed through 1%
formaldehyde- agarose gel. The fractionated RNA was transferred to
nitrocellulose membrane and hybridized to either [32P]-labeled human (a)
E-selectin- specific, (b) ICAM-1-specific, or (c) VCAM-1-specific cDNA
and analyzed by autoradiography. Lane 1, untreated; lane 2, TNF-a
treated; lane 3, supernatant from mock infected cells mixed with TNF-a
(50 units/ml);and lane 4, supernatant from TPV infected cells mixed with
TNF-a (50 units/ml), respectively. (d) G3PDH, a constitutive house
keeping gene, was used as an indicator of mRNA loading. All experiments
were repeated at least three times.
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Figure 7. Selective Down-Regulation of CAMs by Supernatant From TPV Infected
Cells. Primary human endothelial cells were stimulated for 4 hours with
supernatant from either mock infected cells or TPV infected cells, pre
incubated for lhour with either IL-I 13 (A and C) or TNF-a (B, D, and E).
Quantitative ELISA was carried out to monitor the expression of selectin
(A and B), ICAM-1 (C and D) or VCAM-1 (E). Values on the vertical
axis represent the means ± SE ( sd) for triplicate samples. Numbers on the
horizontal axis represent volumes of supernatant from mock infected
cells shown by gray bars and supernatant from TPV infected cells shown
on the right by black bars.
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infected cell supernatant. In contrast, IL-113 induced CAM expression was unaffected
by supernatant from either mock infected or TPV infected cells (Figure 7 A, 7C).
These results indicate a selective down-regulation of only TNF-a induced CAM
expression by supernatant from TPV infected cells.
Inhibition of NF-KB Activation and Translocation
To further explore the nature of inhibition, we investigated the nuclear
transcription factor-kappa B (NF-KB) regulated pathway of CAM gene expression.
NF-KB is a two subunit complex involved in the regulation of numerous genes,
including those involved in the inflammatory response.

NF-KB is bound to an

inhibitory molecule, IKB, in the cytoplasm of unstimulated cells. Addition of pro
inflammatory cytokines such as TNF-a and IL-113 activates a signal transduction
cascade, which leads to the phosphorylation of IKB and the subsequent degradation of
this inhibitory molecule.

The loss of IKB activates NF-KB, resulting in its

translocation to the nucleus where it initiates transcription of CAM genes (reviewed
in Baeuerle, 1991). To determine whether the supernatant from TPV infected cells
was interfering with the NF-KB pathway, we employed gel electrophoretic mobility
shift assays (GEMSAs). GEMSAs would allow us to ascertain activation of NF-KB
by measuring NF-KB DNA binding in nuclear extracts (Figure 8). Unstimulated cells
(Figure 8, lane 1) do not show NF-KB DNA binding activity. However, when these
cells are treated with TNF-a (Figure 8, lane 2), the DNA binding activity of NF-KB

65

1

2

3

4

5

6

',

%lt
.;_�

.·.::?··,

·.� -���fh>·

] NF-kB

....

.,.__._ N-on-specific

..,..._ Excess Probe

Figure 8. Inhibition of NF-KB DNA Binding Activity by Supernatant From TPV
Infected Cells. Confluent HlNEC were either untreated (lane 1 ), treated
with TNF-a. (lane 2), treated with supernatant from mock infected cells
with TNF-a. (lane 5), or supernatant from TPV infected cells with TNF-a.
(lane 6). Nuclear extracts were assayed for NF-KB DNA binding activity
by gel mobility shift assays using radiolabeled oligonucleotide containing
a consensus NF-KB recognition sequence. NF-KB DNA binding can be
. completely inhibited using 50 fold molar excess of unlabeled
oligonucleotide (lane 3) and super-shifted with antibodies to the NF-KB
subunits (lane 4).
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can be seen, as would be expected. Nuclear extracts of cells that were treated with
supernatant from mock infected cells, pre:-incubated with TNF-a (Figure 8, lane 5),
displayed NF-KB DNA binding activity to the same degree as extracts from cells
treated with TNF-a alone. Supernatant from mock infected cells did not interfere
with the DNA binding ability of NF-KB. However, extracts from cells that were
treated with supernatant from TPV infected cells, pre-incubated with TNF-a (Figure
8, lane 6) showed no NF-KB DNA binding activity. These results indicate that active
NF-KB is not found in nuclear extracts from cells treated with the supernatant from
TPV infected cells. This suggests a complete inhibition of NF-KB activation and
translocation by the supernatant from TPV infected cells.
TPV Infected Cells Secrete a 38 kDa Polypeptide That Binds to TNF-a
Taken together, these results show that supernatant from TPV infected cells
selectively inhibits TNF-a induced CAM expression prior to NF-KB activation. This
then suggests that inhibition is at the receptor binding level with a constituent of the
supernatant directly binding to TNF-a and inhibiting it from inducing CAM
expression.

To address this possibility and to identify this component of the

supernatant,

[

35

S]methionine labeled supernatant from TPV infected cells was

examined electrophoretically on an 11.5% polyacrylamide gel (Figure 9A).
Supernatant from TPV infected cells (Figure 9A, lane 2) shows a single polypeptide,
approximately 38 kDa that is not found in supernatant from mock infected cells
(Figure 9A, lane 1). To determine if this polypeptide was binding to TNF-a, a TNF-
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Figure 9. TPV Infected OMK Cells Secrete a 38 kDa Polypeptide That Binds TNF
a.. Infected OMK cells were labeled with [35 S]methionine 2-18 hours post
infection as described under Materials and Methods. (A) Radiolabeled
supernatant was loaded on an 11.5% polyacrylamide gel. Electrophoretic
examination of supernatant from mock infected cells (lane 1) and
supernatant from TPV infected cells (lane 2) are shown. (B) Supernatant
from TPV infected cells was run through a TNF-a. affinity column. The
column was then washed, TNF-a. binding proteins eluted, and each eluted
fraction was analyzed on an 11.5% polyacrylamide gel (lanes 1-6).
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a affinity column was prepared.

[

35

S]methionine labeled supernatant from TPV

infected cells was run through the column, and non-binding proteins removed with
multiple PBS washings. 1NF-a binding proteins were then eluted with IM acetic
acid, and each eluted fraction was analyzed on an 11.5% polyacrylamide gel.
Autoradiograms revealed one major 38 kDa protein band (Figure 9B). This band is
also the same molecular weight as a TPV polypeptide previously described by our lab
(Essani et al., 1994). These results clearly indicate that a 38 kDa protein found in the
supernatant of TPV infected cells binds directly with TNF-a and suggests that this
activity is responsible for the inhibition of CAM expression in TNF-a treated cells.
Identification of the 38 kDa Protein
To identify the TPV 38 kDa protein, concentrated supernatant from TPV
infected cells was prepared and loaded on a 10-20% polyacrylamide Tris-Glycine gel.
Following electrophoresis, proteins were transferred to a PVDF membrane by
electroblotting, and then stained with Coomassie blue for visualization. The 38 kDa
protein band, as determined by low and mid-range markers (Figure 10, lanes 5 and 6),
was excised and directly sequenced using N-terminal analysis by automated Edman
degradation. Sequence analysis provided the amino acid sequence, Ile-Thr-Leu-Lys
Tyr-X-Tyr-Thr-

Val-Thr-Leu-Lys-Asp-Asn-Gly-Leu-Tyr-Asp-Gly-Val-Phe-Tyr-X

His-Tyr-Asn. The amino acid sequence was compared to other proteins using the
program BLASTN (Altschul et al., 1990). Exhaustive search of the protein databank
did not reveal any homology between the 38 kDa TPV protein and any known
protein.
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Figure 10. TPV Infected Cells Secrete a 38 kDa Protein. Concentrated supernatant
from TPV infected cells was prepared as described and loaded on a 10-200/o
polyacrylamide Tris-Glycine gel (lanes 5 and 6). Following electrophoresis,
proteins were transferred to a PVDF membrane by electroblotting, and then
stained with Coomassie blue for visualization. The 38 kDa protein band, as
determined by low-mid-range and low-high range markers (lanes 1-2
respectively), was excised and directly sequenced using N-terminal analysis
by automated Edman degradation. This 38 kDa was not seen in supernatant
collected from mock infected cells (lanes 3 and 4).
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Cloning and Sequencing of the Gene Encoding the 38 k:Da Protein
To isolate the open reading frame (ORF) encoding the 38 k:Da TPV protein,
cloned TPV Pstl DNA fragments inserted into the pUC 19 vector (Pstl fragments F,
H, J, L, M, and N) and genomic TPV DNA were digested with Pstl and
electrophoresed on a 0.7% agarose gel containing ethidium bromide (1.0µg/ml)
(Figure 11). Genomic DNA from OMK cells was run as a control to confirm that the
38 k:Da protein was viral and not cellular in origin. The DNA was transferred by
Southern blotting and then probed with TPV probe-3 (5'-TAT-GAT-GGT-GTT-TTT
TAT-3'). TPV-probe 3 was designed from the N-terminal amino acid sequence of
the 38 k:Da protein. Of the fractionated DNA, only one showed clear and distinct
hybridization to the probe (Figure 11 ). This band was identified as the 5.1 kbp Pstl-J
fragment. The Pstl-J fragment exists between the 10.1 kbp Pstl-D fragment and the
7.9 kbp Pstl-G fragment.
The TPV Pstl-J Fragment
Both strands of the entire 5.1 kbp cloned J fragment were sequenced to
identify the ORF encoding the 38 k:Da protein. The universal M13/pUC forward (5'
CGC-CAG-GGT-TTT-CCC-AGT-CAC-GAC-3') and reverse primers (5'-AGC
GGA-TAA-CAA-TTT-CAC-ACA-GGA-3') were used to obtain the initial sequence.
From this, custom 18- to 24-mer oligodeoxyribonucleotide primers were synthesized
using standard chemistries to primer walk the remaining fragment. A sequencing
scheme is shown in Figure 12. The auto assembler DNA sequence assembly
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Figure 11. TPV Probe-3 Binds to TPV Pstl-J Fragment. TPV Pstl digested cloned
fragments F (9.0 kbp), H (6.6 kbp), J (5.1 kbp), L (2.1 kbp), M (1.4 kbp),
and N (1.1 kbp) were run on a 0.7% agarose gel. Fractionated DNA was
transferred to a nylon membrane and hybridized with [y 32P ATP] labeled
TPV Probe-3 (see tables 2 and 3). Figure shows photograph of ethidium
bromide stained agarose gel (B) and corresponding autoradiogram (A).
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The 5.1 kbp

software was utilized to assemble and edit DNA sequence data.

sequence of the J fragment is displayed in Figure 13. Nucleotide sequence analysis of
the 5.1 kbp Pstl-J fragment using the NCBI ORF finder revealed 7 potential ORFs
(Figure 14). DNA sequence data did not reveal any amino acids with homology to
the 38 kDa protein. Five of the ORFs however did have direct counterparts in the
vaccinia virus. Table 4 lists the ORFs with their respective sizes and homologies.
The TPV Pstl-JlR ORF is predicted to encode a protein of 385 amino acids
with 69% homology to the vaccinia virus, Copenhagen strain H4L ORF found on the
Hindi.II H fragment of the genome (Rosel et al., 1986). The vaccinia virus H4L ORF

encodes the RNA polymerase-associated transcription specificity factor, RAP 94.
The TPV Pstl-JlR ORF is most likely the partial sequence of a larger gene, which
continues on the TPV

TJDI
M13R

TJD5
TJD2b

TJD3

TJD4b

TJUR6b

TJUR5c

5'
TJDR2

TJDR7
TJDR4

Figure 12.
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M13F

Sequencing Scheme for the TPV Pstl 5. lkbp J Genomic Fragment.
Both strands of the 5, 137 bp were sequenced. The universal
M13/pUC forward and reverse were used to· obtain the initial
sequence. From this, custom 18- to 24-m�r primers were synthesized
using standard chemistries to primer walk the remaining fragment.
The TPV Pstl 5.1 kbp J genomic fragment is shown in the 5' to 3'
direction. TPV-J fragment (TJ) up (3') primers are designated with a
U, and down (5') primers are designated with a D.
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1 CTGCAGATGT TATTAAAAAT AACGTAGTCG TTTCAACATT TAACAAGTCT ATATTTTTAA
61 GCGAACCTTA CAGTTATTTT GTTCATAGTC AAAGGTTTAT ATTTAATATT ATTATGTCTT
121 TTGATAATAT TATGAAATCA CAAACATGGG TCATGAAGTA TAATATTAAT AGACTGATAT
181 TAAATTTTTT AATAGAGATA AATTCAAAAC GCCAAAAATA CGAAAAAAAA TTTAACGAAG
241 AAATTAAAAA AGGTGTTTTT TTCCTACGCC TTTCTGCTAA CTTGTTTGAT ATACACGTGT

301 CTTCCACGGA ATTGTTTTAC TCGTCTAAAA TTTTAAATTT AAACTATATA GTAGTTCTTG
361 TTATTGTTTT AAATAGCAGT GCAGATTTTA TAATATCTTA TATGAATTCA AAAAAAAAAC
421 AAATAGATGA AACATCTATT AAATATGCAT TATCTGTAAT AATATACAAT TTTTTATTAA
481 AAACAAAAAT ATGCGAAAAG GGTTCGTTAA ACACAATAAC TTTATTAACG GATGTTTATA
541 CAAGCATTAT GCCAGAAGAA CTTGATTTAC ATTTTAACAG AATATTAATA GAGTTAAAAA
601 AATTAGTCTC TATTAAAAGA TCTGAAAAGA AACCTAATTA TGATGTCGAG GTTAAAATAC
661 TAGACCCGCC GTTAACAAAA ATTAAATTTT TTGACAACTG CTCAATAATC GTTAAAAATA
721 TGATGTTGCC AAATATTAAA GAAAATATTA ATAGAGACAT TATACGGCCA ACATACACGT
781 TTAAATTTAA CAAAAATATG TTTCAACTGT TTAAAATATT AACTACCGAT GAGGACCTAA
841 AAGTTTTAAT TAGATACAAC GACCACACAA ACGCTACAAA GCTTGTTATT TTTCCAACAC
901 ATTTAAAAAT AGAAATAGAA AGAAAAAAGC TAATAATTGC TTTAAAAACA TTGTTTACAA
961 ATAATGTACT AAAATATTAT TATTCCGTTC CTTCATTATA TGTTTTTAGG TTTGGGGATC
1021 CATTTCCATT TGATGATGAA TTAATTGATT CTTTTCATGT TCAGTATAAA GTAAACTGTT

1081 ATAACTTGTT ACGATATCAT ATGTTACCAA ATAGTGACGT TTTTGTTTAT TTTGATAAAT
1141 CTTTAAAAAG AGAAGATTTA GAATATTCAT TTTATATGTT CCTATATAAT TACGTTGGTG
1201 ACGTATCAAC CTGGATTGAT AAAAACATAA CTAGAATTAG AGAGTTGTAC GTAATTAATT
1261 TTAATAATTA AATGGCAAAA AATAATAACG AAATGTTATT AGACGTTCCT ATTTATATTA
1321 TACCAATAGT AAATCGTGGT GTAAAAAGCG TTATTCCAGA GTATGAAGCT GATAAAAAAA

1381 ATGTAGAAAT TGACGAAATA AAAGACGATT CAAAATCTAT AACAGGAAAA GATCTAACAG

Figure 13.

DNA sequence of the 5.1 kbp Pstl-J fragment of TPV Genome. The
sequence is shown in the 5' to 3' direction. Both strands of DNA were
sequenced.

1441 CTATTGCTTA TGAATATTAT ATTTGGAAAA GGGTAGAACA TAGCGGAGGA ATAGAAAGTT
1501 TTAAGGATTA CTTTTCTAGT TTTTGCAACA TAATATGTTC GCAAGAATTA AAAACATCAG
1561 TTTCTAAACA TTTTAGTTTA TGGGAACAGT ACGCAAAAGC TAACATTAAA GATCCAGAAA
1621 AAAAATTTTT TGTAGTATTG GAGGATGACA ATACATTACA TGATTTAACA ACTATTCACG

1681 TTTGTATATC TTCAATGATT GAAAAAAACA TAGACATTTT ACAACTTAGA GAGACAATGT
1741 ATAATAACAA TGTAAGAACG TTATTAAACC CAGGATATAA ACAAGCTATG TATTCATATA
1801 CAGGAGGATA TGATTTTAGT TTGTCTGCGT ATATTATTAG AGTATCTACA GCTATAAGGT
1861 TTATAAATGA AATTAAATCA AAAGGCGGAG TGTCGGCAAG CTTAAATTTT GAATTATCAA
1921 AAATAGAAAA CGATTTAAAG GTAAACAGAC AAGTATTAAA CGATTCTTCA ATTTATGTAA
1981 CTCACGATGC TAGGTTTGTA TCTTATAAAA GGGTTGACGA AAACAGAAAC AAAATGTTAA
2041 ATAAAATAGA AAACTGGATC GCTGGTAGGT TTCCTAATGC GTACTATACC ATAACACATC
2101 CATTATTTTC ATTTTTTGGA CTTTTTGATA TTAACATTGT TGGTATGATA ACTATATTAC
2161 TTATACTAAT TTTATTTATA TTTGAAGTAA ATTCAAAACT TTTATGGTTT CTGTCAGGTG
2221 CAATGTTTTC ATACGTTATA TAATATTAAT TTAACAAATT ATAAAAATCT GAACACCAGT
2281 GAGATTCCAT AAAGTATCCA CTATACCCCA CCTTGTCCAT CATATCCAAT CCACAAGTTA
2341 TGGTATTATC ATAATTTGAT TTAATTATAT GTTCGCAAAA TTGTTGAGCT GATAAGTCTA
2401 CTTTATTTGA TTTTTTAATC ATCCACGCAT CTCCATCTCC CCTTCTTATG GCCTGTGGCA
2461 AAAAACTTTT TTTATCTATT CGCGCTGCAA CAAAATATGG TCCATAATCT AAACAATTAA
2521 ACACGTATAA ATCGTTTCTG TCGGATGATA TTAGTCTGCC CCTATCGCTC TCTAATTTTG
2581 TTTTTGATTC AACTAACGGT CTCCACCCCT TTACAGAATT TTTAATTCTA ACATACTTTG
2641 CAAGTTCTGA AAAAAAAGAA TTTTTAGAAA CTTGGAACCA AAACAACAAA ACACTTGCAG
2701 ATAATATAAT TACAAAAAAG CAAAGAGTTG ATCTTTTGGC AGCCTGTACA CTTTTTGCAT
2761 TTTTTTCACG TACATATTCC AATTCTAACC CATTAACGGT TAATGTTGTT TTATCCATTT
2821 GTAGATATTA TAAATGGATA AAAAATGTAT ATATGAAAAC GTTTTATTAA AGTCAACAGG

Figure 13.
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2881 ATTGTTACCT AAAGCTAAAG CTCCAACAAA AATGACGAGG GTAACAGACT ATGTATATTT
2941 AGGAAATTAT AATAACGCAT TATCTATTAA TGAATATGGT ATACAGTTTA AATATATTTT
3001 AAATTTAACA ACTGAAAAAT ATAAAATTTG TAACTCGTCA GTAAATATAA TTCATATGCC
3061 TTTATTGGAT AACGAAACAA CAGATTTAAC AAAACATTTT GATTACGTAA CAAACTTTTT
3121 ATCTAAATGT GATAAAAATC ATTATCCGGT ATTAGTTCAT TGTATTGCAG GTGTTAACAG
3181 AAGCGGTGCG ATGATTATGG CATATTTAAT GACAAAAAGA AACAAGGATG TTCCAGCTTT
3241 TATGTTTTTT TTATACGTTT ATCACTCAAT GCGAGAACAG AGAGGTGCAT TTTTAGAAAA
3301 TCCGTCTTTT AGAAAACAAA TTATAGAAAA ATACGTTATA AAAAACTAAA AGTCCTCTAC
3361 TAATTCAGTT AACATTTCAA CCTTTTGTTT AGCAATTTTT ACAGAAAGTT TTTTTTCTAA
3421 TCTTGTCAGT AGCTCTAAGT TAACAAAATA TCTATAATAC CCTGTACCGA TTTTTGGAAC

3481 TTTACTGAAA AAATGACAAC TACTATTATC ATTAACATGT TCTGATTTTT TATGGAGTGC
3541 TGCGTTTAGT AAAGCTTTAT TATCCCAAAG GTGGCTTTTT TTAACGCAGT TGCAGATCCA
3601 AACTTAAATT TATTTACTGA TTCTGGTTCG TAACTCATAC ATATTAAACT AGATAAAAGA
3661 TCACATGGTT GGTATAAATA ATCAAAACCC TCCTCCATAA GTGTTTTAAT AACGCTTCCG
3721 CACAGATATC CTCTGGCAGA TTCTATTCCA AAAATATCAT AAGTGTTCCA TATTCCTGTA
3781 TAAACATTTA CATCTTNTAA GTCAAATGTT CCTAATTCTT TTAAATTCAT TAATTCAACA
3841 GTCATTTTAT ACATTTTTTT TGTTTTGTTA AAATCTTCAT AACATACATA ATCATATATT
3901 GGTATTTTAA ACTTGCTAAT TTTTCCTTTG TTTACAGCGC CTAATAACAC CATCATAAAT
3961 TTATTAAGAT TTAATTCTTC AGGTTCTACA AATTTTGAAT ATATTGTATA TTTTATATTA
4021 TTTTCGTCGT GTATATTAGT TTCTAATCCC CACTCTTTAA CAAGAACACT AAATGAAATA

4081 AATCTTTCTA TCATATATTC AACTACCAGT TCTGTTAACT CCGCTCTTTT TATATAAACC
4141 CTATTGACGA TAATATCGAT AATAAATACA TCTTTATCCT TGCCAAGGTT TATTATTGGA
4201 TTTAATTCAC CTAAACAAAC AAATTCAAAA TTTATTTTAA CGTTTTGTAA CTTTGCAACA
4261 TCATCCGAAA TTAAAGTAAT AATTTCCGTT TTGTTTTTAC TTAAGTTTGT AAGGTTATTA

Figure 13.
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4321 AACTCATTAA AACCAAGTTT ATGTTTTACC GCTCCACTTT TTTCTGTTGT GTGAAAACTC
4381 GATAACGCCT GTTGTGTAAA TTTTTCAGAT AAAACCTGGG CGGAAATAAT ACCTATTGGA
4441 GTTCCACCTC CTAACGAGTA GTTTAACTTT TCGTAAAATT TTTTAAAAAT ATTTATTGCT
4501 GTATTTGTAG ATATCTTAAC CCTAGCAGGA TTAAGATGAG TTAAAAACAC ATACTCTATA
4561 AAATCAATAT TTGTAATTGT AAAAAAGTAC TTTTCCTTTA CATCCTCCAA AACGTTTTGA
4621 ATCATATCGT ATAACTTTTT TGCTCCTATT GAATTATTTT TATCAGATTC TTCTATAAAC
4681 ACTAGAAAGT TAAACGGAGC TAAGGTTTTT TTAATTATTT TTTGTCTTTG AGAATATATA
4741 AATCCTTTTT TTATTTTTTC CCATAATGCA CTTATTTCTA AAAACCAAGT CATCGATTCA
4801 TGTGGAAAAA TTAATTCAAC TGGTTTACAT ATAGATGCCA ATATTTTTGT GTAATTTGCG
4861 CTATATTTTA AAAGAATATT GCCATATACA ACCTGTCCAT AACCGTCAAC GACCATATCT
4921 TCCATTTTTT TAATTATTTT CCTTGCCAAT GTTCCAGTTC TGGATGTTTC ACATACTATG
4981 TCTGTAGATT GTGACCGTGC AACTAACATT GAAAAATAGT ATTGAGAACC AGTTAAACCC
5041 TGTGTTAAAG AGTTTAATAT ATATCCTCTT CCCTCTGGAT CCTTAGAATT GGGAAAATAG
5101 TAAGGCAACA CCCTTCCTAA AACTTTAGTT TCTGCAG

Figure 13.

continued from previous page.

E

L H MN

B

K K

A

C

D

J

G

F

I

scale
1 inch =20kbp

Obp

)

JlR

5137bp

5'

3'

3'

5'

J2L

lcm=250bp

�

J3L

Figure 14.

L__J

JSL

J7L

Pstl Restriction Map of the TPV Genomic DNA and Location of the Potential ORFs on the Pstl J Fragment.
(A) The Pstl restriction map of the TPV genome is shown with fragments A through N designated according to
their sizes. (B) The potential ORFs on the J fragment are shown with respect to the 5', 3' sequence of the J
fragment.
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Table 4
Putative Open Reading Frames ofthe TPV Pstl-J Fragment
ORF

Size (Bases) MW(kDa)

Homologies

JlR

1158

4 2.9

91% to vaccinia H4L homolog ofYaba virus
69% to vaccinia H4L protein- encodes RNA
polymerase-associated transcription specificity
factor (RAP94)

J2L

1 23

4.6

no significant homology found

J3L

165

6.1

37% to feline sarcoma virus tyrosine kinase
transforming protein
37% to human macrophage colony stimulating
factor I receptor precursor (CSF-1)
37% to feline sarcoma virus CSF-1 receptor
oncogene homolog

J4R

972

36.0

80% to vaccinia H3L homolog ofYaba virus
51% to P32 antigen ofsheeppox virus
35% to vaccinia immunodominant envelope
protein P35

J5L

573

21.2

84% to vaccinia H2R ofhomolog ofYaba virus
62% to vaccinia virus H2R-late protein
26% to human T-cell receptor a-chain precursor
V- region

J6R

516

19.1

88% to vaccinia HlL homolog ofYaba virus
63% to vaccinia protein-tyrosine phosphatase
(late protein Hl)
29% to human dual specificity protein
phosphatase 7

54.2

91% to vaccinia J6R homolog ofYaba virus
78% to RNA polymerase subunit rpo 147 of
vacc1ma virus
79% to myxoma virus m68R

J7L

1464
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sheeppox virus H4L homolog, 72% to the myxoma virus H4L homolog (m72L), 73%
to the rabbit fibroma virus H4L homolog (gp072L), 68% to variola virus H4L
homolog (ORF5L), 58% to the molluscum contagiosum subtype 1 H4L homolog
(mc085L), 48% to the orf virus H4L homolog (F2L), and 22% to the Melanoplus
sanguinipes entomopoxvirus H4L homolog (msvl 19).
The TPV Pstl-J2L ORF is predicted to encode a 40 amino acid protein, which
has no significant homology to any known proteins. The TPV Pstl-J3L ORF is
predicted to encode a 54 amino acid protein which shows 37% homology to the
transforming protein of the McDonough strain of feline sarcoma virus (FSV) and
37% homology to the human macrophage colony stimulating factor-I (CSF-1)
receptor precursor.

The carboxyl terminus of the FSV transforming protein

interestingly has homology to the tyrosine-specific protein kinases encoded by many
known retrovirus oncogenes (Hampe et al., 1984).
The TPV Pstl-J4R ORF is predicted to encode a protein composed of 323
amino acids. This protein shows 80% homology to the vaccinia virus H3L homolog
of the Yaba virus, 52% homology to the P32 antigen of the lumpy skin disease virus,
51% homology to the sheeppox virus P32 antigen, 35% homology to the IMV
membrane associated protein encoded by the H3L ORF of the vaccinia virus, and
35% homology to the H3L protein of the variola virus. The TPV Pstl-J4R ORF
contains a translation initiation site, TAAATGG, at the start of the ORF and therefore
most likely encodes a late protein.
The TPV Pstl-J5L ORF is predicted to encode a 190 amino acid protein,
which shows significant homology to the vaccinia virus H2R ORF (62%). There is
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84% homology to the H2R homolog of the Yaba virus, 64% to the H2R homolog of
the sheeppox virus, 63% to the myxoma virus H2R homolog, 61% to the rabbit
fibroma virus H2R homolog, and 52% to the molluscum contagiosum virus H2R
homolog. The vaccinia virus WR strain H2R encodes a late protein called H2.
Interestingly the TPV Pstl-J5L ORF also shares 26% homology with the human T
cell receptor-a chain precursor V-region.
The TPV Pstl-J6R is predicted to encode a 171 amino acid protein, which is
the TPV protein-tyrosine phosphatase gene and shows notable homology to the
vaccinia virus tyrosine phosphatase encoded on the HlL ORF.

The vaccinia virus

HlL protein is a soluble protein with dual tyrosine and serine specificity (Guan et al.,
1991).

This protein is essential to the virus and allows it to dephosphorylate

phosphotyrosyl and phosphoseryl residues in tissue culture (Guan et al., 1991). The
TPV Pstl-J6R also shows significant homology to other poxvirus tyrosine
phosphatases (Mossman et al., 1995a) including Yaba virus (88%), myxoma virus
(76%), sheeppox virus (75%), rabbit fibroma virus (75%), and variola virus (63%).
The vaccinia virus protein-tyrosine phosphatase is encoded by a late gene with a late
translation initiation site found upstream of the 5' end of the ORF. This TAAATGG
sequence is found on the TPV Pstl-J7R ORF but at the 5' end.
The TPV Pstl-J7L ORF is the largest gene encoded on the TPV Pstl-J
fragment and is located at the 3' terminal. The Pstl-J7L protein shows significant
homology to the RPO147 subunit, of the vaccinia virus DNA-directed RNA
polymerase (Broyle and Moss, 1986). The RNA polymerase subunit, encoded on the
vaccinia virus J6R gene, is a 147 kDa polypeptide. Our Pstl-J7L ORF encodes a 487
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amino acid protein (54.2 kDa) which appears to be the partial sequence of a larger
one. The remaining protein sequence may be encoded on the 7.9 kbp TPV Pstl-G
fragment. ThePstl-J7L ORF shows 91% homology to the Yaba virus J6R homolog,
70% to the myxoma virus J6R homolog (m68R), 79% to the rabbit fibroma virus J6R
homolog (gp068R), and 88% to the sheeppox virus J6R homolog.
To summarize, the Pstl-J fragment is 5,137 bases in length and potentially
encodes 7 major ORFs. Two of these ORFs, the TPVPstI-JIR and -J7L, are partially
encoded and are found at the 5' and 3' terminals respectively. Late genes, Pstl-J4R
and -J6R, contain the translational initiation sequences, TAAATGG as determined for
vaccinia virus (Rosel et al., 1986). The TPV Pstl-J7L is the largest ORF and shows
78% homology to the vaccinia virus J6R gene encoding the DNA-directed RNA
polymerase 147 kDa subunit. This gene is highly conserved among other poxviruses
including the myxoma virus, the sheeppox virus, the rabbit fibroma virus, and the
variola virus. The TPV Pstl-J6R ORF has significant homology with the vaccinia
virus HI L encoding tyrosine phosphatase. There is 80-91% sequence homology
between Yaba virus and TPV.

DISCUSSION
Much of the information on poxviruses stems from extensive studies on the
vaccinia virus, which has become the prototype of the poxviruses. The viruses
included in the Yatapoxvirus genus, however, are relatively uncharacterized in
comparison to the vaccinia virus. The members of this genus, Yaba virus, Yaba-like
disease virus (YLDV), and TPV are three distinct viruses. DNA restriction maps
illustrate the extent of differences between the Yaba virus, YLDV, and TPV (Knight
et al., 1989).

All three viruses included in the genus, Yatapoxvirus have been

reported to be immunologically related (Niven et al., 1961, Downie et al., 1971).
The serological similarities between YLDV and TPV and the relatedness of
clinical disease they produce in man and monkey led to the early misidentification of
the two viruses as one (Downie and Espana, 1973 ).

This continues to cause

ambiguity in the nomenclature between YLDV and TPV. ATCC retains stocks of
virus which it identifies as TPV although restriction endonuclease analysis in our
laboratory shows that the virus is actually YLDV. Exhaustive search of the early
literature reveals that TPV was originally isolated from human skin lesions and that
Yaba virus and YLDV were originally isolated from monkey lesions (Downie et al.,
1970, Bearcroft and Jamieson, 1958, Espana, 1966Hall and McNulty, 1967, Crandell
et al., 1969, Espana, 1971). Although Knight et al. (1989) recognize YLDV as the
causative agent of disease in monkeys and TPV as the causative agent of human
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disease, it is now clear that both viruses cause identical disease in humans and
monkeys (Hall and McNulty, 1967, Crandell et al., 1969, Downie, 1974).
Initial work conducted in our laboratory demonstrated that supernatant from
TPV infected cells possessed multiple anti-cytokine activities. This was demonstrated
using cytokine (IL-2, IL-5, IFN-y) binding and inhibition assays (Essani et al., 1994).
This activity was not seen in supernatant from uninfected cells. SOS-PAGE analysis
confirmed the presence of a single 38 kDa protein in the supernatant from TPV
infected cell that was not detected in the supernatant from uninfected cells. This
protein was, therefore, postulated to cause the inhibition of all three cytokines.
Knowing the anti-cytokine potential of the supernatant from TPV-infected cells, we
were interested to investigate the effects of the supernatant on cell adhesion molecule
(CAM) gene expression and NF-KB regulation. This dissertation reports the selective
inhibition ofTNF-a induced CAM expression and the inhibition of NF-KB activation
mediated by a 38 kDa protein secreted from TPV-infected cells and not uninfected
cells.
In order to survive, animal viruses have evolved mechanisms to interfere with
the potentially lethal host inflammatory response. TNF-a is one of the central
mediators in the inflammatory response. TNF inactivation enables the virus to evade
this host anti-viral defense. The results presented here demonstrate that supernatant
from TPV-infected cells contains an activity capable of selectively down-regulating
the expression ofTNF-a induced, but not IL-1J3 induced, endothelial CAMs (Paulose
et al., 1998). CAM expression appears associated with the presence of a TNF-a
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binding, 38 kDa protein found only in the supernatant from TPV-infected cells.
Other poxviruses have been shown to encode proteins with homology to the TNF-a
receptor, for example the Shope fibroma virus T2 protein (Smith et al., 1991), the
myxoma virus MT-2 protein (Upton et al., 1991), and the CrmB and CrmC proteins
of the cowpox virus (Hu et al., 1994). The results presented here provide evidence
that the 38 kDa protein found in the supernatant from TPV infected cells binds
directly to TNF-a. and inhibits it from activating the NF-KB regulated CAM pathway.
It appears that this may be the same protein from TPV that has previously been
shown to bind to hIL-2, hIL-5, and IFN-y (Essani et al., 1994). The ability of a single
viral polypeptide to bind multiple host cytokines illustrates the evolutionary and
genetic efficiency of the virus in its attempts to overcome the host anti-viral response.
The concept of multi-functional viral proteins however is not limited to the protein
described here. The parainfluenza virus (Kingsbury, 1990), the Kaposi's sarcoma
associated herpesvirus (Kledal et al., 1997), the adenovirus (Hoffman et al., 1992),
the myxoma virus (Macen et al., 1996, Lalani et al., 1997), and the cowpox virus
(Tewari and Dixit, 1995) also express proteins with multiple biological activities.
The CrmA protein of the cowpox virus, for example, inhibits both interleukin-I J3
production and cytokine-induced apoptosis (Tewari and Dixit, 1995). The myxoma
virus MT7 protein binds to IFN-y (Upton et al., 1992) and in addition also interacts
with members of the chemokine superfamily involved in the inflammatory response
(Lalani et al., 1997). The MT2 protein of the myxoma virus binds and inhibits TNF
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and also blocks apoptosis by a mechanism that is independent of TNF (Upton et al.,
1991, Macen et al., 1996).
This multiple cytokine binding property does raise questions concerning the
mechanism(s) involved in the binding. One possibility is that hTNF-a, hIL-2, hIL-5,
and h.IFN-y share a common binding site. Alternatively, there may be an accessory
protein (either cellular or viral) that acts as a bridge between the cytokine and the 38
kDa protein. To address this question and to further characterize the TPV 38 kDa
protein, attempts were made to identify and isolate the gene encoding it.
The TPV 38 kDa protein was isolated and subsequently 25 ammo acid
residues were sequenced from the unblocked N-terminus. This sequenced peptide
showed no homology to any known proteins. Multiple TPV-oligonucleotide probes
were designed from the 25 amino acid sequence (Table 3). In the numerous blots and
hybridizations that were carried out, only TPV-probe 3 hybridized to the genomic
TPV DNA Figure 11 illustrates these results. TPV-probe 3 hybridized to the Pstl-J
fragment of the TPV genome. TPV-probe 3 failed to hybridize to any of the other
fractionated genomic TPV DNA fragments. The Pstl-J fragment was isolated and
both strands of the entire 5.0 kbp fragment completely sequenced. DNA sequence
data did not reveal any amino acids with homology to the 38 kDa polypeptide.
However, there were 15 bases that were 100% identical to the TPV-probe 3 sequence,
which may have resulted in the specific binding of the probe. Multiple attempts were
made to isolate the ORF encoding the 38 kDa protein, but none were successful. The
degeneracy of the genetic code, the sequences of the probes, and the low stringency
of hybridizations probably contributed to the failure. However, sequence analyses of
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the TPV Pstl-J fragment reveals 7 potential ORFs with significant homology to the
Yaba virus. The Pstl-J7L ORF encodes the partial sequence of the TPV DNA
directed RNA polymerase. There is significant conservation between the TPV Pstl
J7L gene and other poxviral RNA polymerase genes. The Pstl-J6R ORF shows
notable homology to the vaccinia virus tyrosine phosphatase gene.

The gene

encoding the tyrosine phosphatase was shown to be an essential gene in the myxoma
virus and the Shope fibroma virus possessing dual specificity to tyrosine and serine
(Mossman et al., 1995a).

The TPV Pstl-J2L ORF shows homology to the

transforming protein of the feline sarcoma virus which has homology to the tyrosine
specific protein kinase encoded by many known retroviral oncogenes (Hampe et al.,
1984).

The TPV Pstl-J2L gene may be an additional virulence factor encoded by

TPV. The potential ORFs found on the TPV Pstl-J fragment are located near one
another and many times the adjacent strand ORFs overlap. This is similar to the gene
organization described for vaccinia virus (Rosel et al., 1986, Traktman, 1990a).
Poxviruses are unique among animal viruses. Their genomes are large and
inclusive ranging from 130 kbp in the parapoxvirus (Menna at al., 1979, Robinson et
al., 1987) to approximately 300 kbp in avipoxviruses (Hyde et al., 1967). This

enables the poxviruses the ability to encode a vast array of proteins needed for
replication, transcription, and virulence. Poxviruses have evolved to acquire one of
the most impressive arrays of genes encoding proteins for immune evasion. Many of
these genes encode homologs of host immune components.

In the past ten years,

there has been a significant advancement in our understanding of these virally
encoded immunomodulating viral proteins. These viral homologs contain a multitude
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of information on the immune response and viral infection. They may in turn lead to
new strategies for novel anti-viral and anti�inflammatory therapeutics.
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